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Abstract 
The rat embryonic cardiomyoblast-derived H9c2 cell line is increasingly used for 
studies into cardioprotection, as these cells display similar properties to primary 
cardiomyocytes.  Adenosine receptors are well known mediators of cardioprotection 
and trigger effectors such as the mitochondrial KATP channel – however, the role of 
the mitochondrial BKCa channel in adenosine receptor-mediated cardioprotection has 
not been investigated.  GPCR assays provided evidence for functional expression of 
Gi-coupled adenosine A1 and κ-opioid receptors, Gs-coupled β2 adrenergic receptors 
and Gq-coupled UTP-binding P2Y purinergic receptors on H9c2 cells.  Activation of 
the adenosine A1 receptor with CPA (N(6)-cyclopentyladenosine) provided 
significant protection against hypoxia-induced cell death in these cells, as did 
opening of a BKCa channel with NS1619.  The location of this BKCa channel was 
confirmed to be the mitochondria by the probing of subcellular fractions with BKCa-
specific antibodies.  Interestingly, CPA-induced protection against hypoxia was 
blocked by inhibition of the BKCa channel.  In a model of hypoxia/reoxygenation in 
H9c2 cells both CPA and NS1619 significantly reduced cell death when used as 
postconditioning agents, and in both cases the protection was abolished by blockade 
of the BKCa channel.  This data suggests for the first time that, in H9c2 cells, the 
BKCa channel is involved in A1 receptor-mediated cytoprotection.  To confirm this 
finding in a more physiologically relevant model – and validate the use of H9c2 cells 
as a model for cardioprotection –hypoxia/reoxygenation in isolated rat ventricle 
strips was investigated.  It was discovered that blockade of the BKCa channel 
significantly attenuated protection afforded by hypoxia preconditioning and 
preconditioning triggered by activation of the adenosine A1 and A2A receptors. 
For the first time, this report has shown an important role for the BKCa channel in 
adenosine receptor-mediated cytoprotection. 
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1. Introduction 
1.1. Cardiovascular disease  
Cardiovascular disease is currently the leading cause of death in the developed 
world, with ischaemic heart disease accounting for over 94,000 deaths in the United 
Kingdom in 2006 alone (British Heart Foundation Statistics Database).  Although 
heart disease is often thought to be an affliction of the elderly, since risk does 
increase with age, it is also the foremost cause of premature death in the UK in men 
and women (British Heart Foundation Statistics Database).  Ischaemic heart disease, 
or coronary heart disease, is caused when a coronary artery becomes blocked - often 
as a result of a thrombus or atherosclerotic plaque.  Blood flow to myocardial tissue 
is reduced leading to symptoms such as dyspnea, angina pectoris and myocardial 
infarction.  As the populace increases in age, and risk factors such as obesity and 
diabetes become more common, the incidence of ischaemic heart disease will be 
raised – creating a substantial burden on the National Health Service.  Research 
regarding the mechanisms involved in cardiac ischaemia and protection against the 
resultant tissue damage is plentiful, but as yet very few pharmacological agents have 
successfully transferred from producing positive experimental data (in cell and 
animal models) to encouraging clinical outcomes.  Therefore, any insight into the 
complex pathways involved in ischaemia and ischaemia/reperfusion injury could 
help identify future, or potentiate existing, targets for therapy.   
1.2. Ischaemia and ischaemia/reperfusion-induced cell death  
Myocardial cells exhibit a variety of metabolic responses to ischaemia; the extent of 
the response depends on the degree of ischaemia experienced by the cells and so not 
all myocytes exhibit the same behaviour.  Cellular responses to ischaemia include 
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myocardial stunning, hibernation and preconditioning.  The phenomena of 
myocardial stunning has been described in a number of animal models including the 
isolated rabbit heart (Flameng et al, 1991) and dogs (Phillips & Ko, 2007), and has 
also been proven to occur in humans (Gerber et al, 1999).  It describes the delayed 
return of myocardial contractile function following ischaemia, despite full restoration 
of blood flow, so allowing myocytes time to “repair” during a period of reduced 
energy requirement (Depre & Taegtmeyer, 2000).  Alternatively, repeated stunning 
may lead to myocardial hibernation (Kim et al, 2003).  This is often in response to 
chronic ischaemia/hypoxia and is a process where myocardial function is lessened in 
alignment with the reduced supply of oxygen and nutrients.  These processes allow 
irreversible tissue damage to be avoided, so upon restoration of normal blood flow 
contractile function can eventually return.  Another process that can occur in 
response to ischaemia is preconditioning, which enhances the resistance of the 
myocardium to irreversible damage and will be described later on in more detail (see 
section 1.4). 
During ischaemia the reduced availability of oxygen and metabolic substrates is 
insufficient to support normal oxidative phosphorylation.  This triggers the 
mitochondria to switch from aerobic to anaerobic respiration, so reducing formation 
of ATP and producing intracellular acidosis with accumulation of hydrogen ions (H
+
) 
and lactate (see Figure 1.1, page 12).  This leads to inhibition of the ATP-dependant 
sodium/potassium pump (Na
+
/K
+
-ATPase) and activation of the sodium/hydrogen 
exchanger (NHE) – both of these actions augmenting intracellular Na+ accumulation.  
The increase in Na
+
 activates the Na
+
/Ca
2+
 exchanger, leading to intracellular 
accumulation of Ca
2+
.  Osmotic swelling occurs due to influx of Cl
-
 and H2O.  The 
reduction of ATP also reduces uptake of Ca
2+
 by the sarco/endoplasmic reticulum 
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Ca
2+
-ATPase (SERCA), so further intracellular Ca
2+
 accumulation occurs.  Ca
2+
-
dependant proteases are then activated, causing damage to the membranes and 
cytoskeleton.  This, combined with the swelling of the cell, can lead to membrane 
rupture and oncotic necrosis.  Oncosis, or “ischaemic cell death” (Schaper & Kostin, 
2005), is a form of accidental cell death caused by failure of ion pumps.  It is 
characterised by cell swelling, increased membrane permeability, blebbing and non-
specific DNA degradation (Majno & Joris, 1995).  In the literature the term 
“necrosis” is often used in place of oncotic necrosis, however, necrosis specifically 
refers to the changes that occur following any kind of cell death.  This is 
characterised by further changes to the nucleus and cytoplasmic constituents and 
breakdown of the plasma membrane; up until this point it is thought that cells can be 
rescued, and the onset of necrosis represents irreversible cell death (for review see 
Trump & Berezesky, 1996).  To remain consistent with the literature, from this point 
“necrosis” will be used to describe non-apoptotic cell death in this report.    
Apoptosis is a distinct form of cell death and can be initiated by a cell’s “internal 
clock” or an external signal (Majno & Joris, 1995).  Unlike necrosis, it is 
characterised by cell shrinkage, nuclear condensation and specific nuclear cleavage, 
and budding of apoptotic bodies – these are then phagocytosed without stimulating 
an inflammatory response.         
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Fig.1.1: Proposed series of events leading from myocardial ischaemia to irreversible cell 
death.  The reduced formation of ATP and intracellular acidosis caused by lack of oxygen 
disrupts ion transporters within the cell, leading to cell swelling and damage – resulting in 
irreversible necrosis. 
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It was originally thought that necrosis was the predominant form of cell death 
initiated by hypoxia/ischaemia, and there is evidence for and against a role for 
apoptosis.  For example, hypoxia-induced apoptosis has been detected in neonatal 
and adult rat cardiomyocytes (Tanaka et al, 1994; de Moissac et al, 2000), but a 
study by Webster et al (1999) reported that apoptosis could only be measured when 
hypoxia was accompanied with reoxygenation or a shift in pH – and this was found 
to be the case in neonatal rat cardiomyocytes and the Langendorff-perfused mouse 
heart.  Such discrepancies may arise due to the model used, different conditions for 
hypoxia and/or different methods of measuring apoptosis.  It has been shown that 
different apoptotic pathways can be stimulated depending on culture conditions; one 
study utilising Jurcat cells (Malhotra et al, 2001) described caspase-3-dependent 
apoptosis following hypoxia in a glucose-free medium, but caspase-3-independant 
apoptosis following hypoxia in glucose-containing medium – suggesting that a 
caspase-independent death receptor pathway had been activated.  Overall, the data 
regarding hypoxia-induced cell death is varied, but a there is a large body of 
evidence in favour of a role for apoptosis.   
However, it is now believed that a combination of apoptosis and necrosis occurs – 
with apoptosis being the preferred pathway until ATP levels are too low to sustain 
the energy-dependent process, after which necrosis takes over (Tatsumi et al, 2003; 
Otani et al, 2006). 
Initially the damage observed in myocardial tissue following an infarction (in the 
clinical setting and experimental models) was believed to be inflicted purely during 
the period of ischaemia.  However, in 1987 Olafsson et al provided evidence that 
some injury occurs due to the reinstatement of blood flow during reperfusion.  The 
Olafsson group used a canine model and reported that treatment with adenosine for 
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the first hour of reperfusion after a 90 minute period of ischaemia reduced infarct 
size and improved ventricular function compared to untreated controls (Olafsson et 
al, 1987).  The observation that the outcome of the ischaemic insult could be 
improved by pharmacological treatment during reperfusion suggested that some of 
the damage was generated at this stage.  Since this report it has been found that 
treatment with several pharmacological agents at the start of reperfusion can ease 
myocardial injury (for review see Gross & Auchampach, 2007). 
Reperfusion is essential to “rescue” the ischaemic tissue, but it is now known to lead 
to further problems such as arrhythmia, decreased contractile function and 
irreversible cell death.  During ischaemia neutrophils accumulate at the damaged 
tissue, and this process is accelerated upon reoxygenation (Hansen, 1995). 
Neutrophils release ROS, proteases and inflammatory mediators, which in turn 
recruit more neutrophils so amplifying the inflammatory-like response (Jordan et al, 
1999).  Alongside the inflammatory-like response, mitochondria are thought to be the 
main mediators of reperfusion injury (see Figure 1.2, page 15); it is postulated that 
the reintroduction of oxygen re-energises the mitochondrial respiration machinery, 
leading to excessive production of reactive oxygen species (ROS) (Korge et al, 
2008).  SERCA (Sarco/Endoplasmic Reticulum Ca
2+
-ATPase) is activated when 
ATP production proceeds, placing the sarcoplasmic reticulum under severe calcium 
overload.  Calcium is released via ryanodine receptors then taken up again by 
SERCA – this leads to intracellular calcium oscillations and mechanical irregularities 
(Piper et al, 2006).  The accumulation of calcium activates Ca
2+
-dependant proteases, 
such as calpains, which degrade intracellular proteins and compromise the integrity 
of the cell membrane. 
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Figure 1.2: Proposed series of events leading from myocardial ischaemia/reperfusion to 
irreversible cell death.  Upon reoxygenation the increase in oxygen and activation of 
neutrophils sets off a series of events.  Ccommon features of both pathways are excessive 
ROS production and activation of the mPTP – eventually culminating in cell death. 
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1.3. A role for the mitochondria 
Precise regulation of cytoplasmic potassium ion concentration is essential to 
maintain ion homeostasis and cell volume, and it is thought that K
+
 homeostasis is 
the main regulator of mitochondrial matrix volume.  Efflux of K
+
 from the cell can 
lead to osmotic shrinkage, which stimulates mitochondrial release of cytochrome-c, 
activation of executioner caspase-3 and eventual cell death.  This intrinsic apoptotic 
pathway is mediated by the mitochondria. 
Mitochondria are responsible for generating cellular energy in the form of ATP via 
oxidative phoshorylation.  Oxidative phosphorylation involves generation of a proton 
gradient across the inner mitochondrial membrane by the electron transport chain; 
inner membrane-bound ATP synthase then utilises the gradient to power the 
production of ATP from ADP and phosphate (Pi).  If ATP synthesis is disrupted the 
whole cell is affected as ion homeostasis is disturbed, leading to a change in cell 
volume.  
Several ion channels have been described that are located on the mitochondrial inner 
mitochondrial membrane, including two K
+
 channels – the ATP-sensitive potassium 
channel (mitoKATP) and the large-conductance calcium-activated potassium channel 
(mitoBKCa).  Both of these channels have been implicated in cardioprotection against 
ischaemia/reperfusion injury (for review see Nishida et al, 2009).  The proton 
gradient across the mitochondrial membrane (formed by the mitochondrial electron 
transport chain) leads to a negative potential in the mitochondrial matrix compared to 
the cytosol, and this leads to Ca
2+
 influx into the mitochondria (Gunter & Pfeiffer, 
1990).  During ischaemia, when conditions favour Ca
2+
 influx, activation of K
+
 
channels partially depolarises the mitochondrial membrane so reducing the negative 
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gradient, and this attenuates the potentially damaging Ca
2+
 influx.  This has been 
shown in an isolated cardiac mitochondrial preparation using the KATP openers 
diazoxide and pinacidil, and in intact cardiomyocytes with diazoxide 
(Holmuhamedov et al, 1999) and the BKCa channel opener NS1619 (Sato et al, 2005) 
– in each case treatment with the channel openers depolarised the mitochondrial 
membrane and reduced mitochondrial Ca
2+
 uptake. 
It is thought that activation of the mitoKATP channel evokes cardioprotection through 
a pathway involving inhibition of the mitochondrial transition pore (Facundo et al, 
2005; Krolikowski et al, 2005), however, the precise mechanisms by which 
mitoKATP channels mediate cardioprotection are debatable.  The structure of 
mitoKATP channels is not fully known, but it is postulated that they are similar to 
the plasma membrane KATP channels and are composed of an inward rectifier 
potassium channel subunit (Kir) associated with a sulfonylurea receptor (SUR) 
(Mironova et al, 2004; O’Rourke, 2004).  The cardioprotective role of the 
mitochondrial BKCa channel will be discussed later on (see section 1.7).  
Not all mitochondrial channels exert such a cardioprotective effect.  Also on the 
inner mitochondrial membrane is the mitochondrial permeability transition pore 
(mPTP), which is thought to be a key player in ischaemia/reperfusion injury.  The 
mPTP consists of several proteins spanning the inner and outer mitochondrial 
membranes, so allowing the passage of solutes <1.5 kDa through the usually 
impermeable inner mitochondrial membrane.  The structure of the mPTP is under 
debate, but the main components are proposed to be adenine nucleotide translocase 
(ANT), cyclophilin-D (CyP-D), mitochondrial phosphate carrier (PiC) and voltage-
dependent anion channel (VDAC) – although recent evidence contrasts the original 
model for the mPTP where VDAC had a major role.   
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The mPTP opens in response to an increase in mitochondrial Ca
2+
, facilitating the 
release of pro-apoptotic molecules into the cytosol (Rodriguez-Enriquez et al, 2004); 
though during periods of increased oxidative stress the mPTP is sensitised to Ca
2+
, so 
increased Ca
2+
 is not actually required for pore opening (Halestrap et al, 1997). 
However, when ATP depletion occurs to an extent that is too low to support 
apoptosis the mPTP can also mediate necrosis (for review see Crompton, 1999; see 
Figure 1.3).   
ATP hydrolysis
Impaired energy 
metabolism
[Ca2+]i deregulation
Collapse of energy and
[Ca2+]i regulation
NECROSIS
Cytochrome c
Activation of the
caspase cascade
APOPTOSIS
 
Figure 1.3: Regulation of cell death by the mPTP.  Mitochondrial permeability transition 
can set off a series of events culminating in necrotic and/or apoptotic cell death. (Green/blue 
bars, open mPTP). 
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It has been suggested that mPTP is formed by a CyP-D-facilitated conformational 
change of the PiC, and that this is modulated by the conformational state of an 
associated ANT (Halestrap et al, 1997; for review see Halestrap, 2009).  Evidence 
for these associated proteins arises from various reports.  For example, it has been 
shown that livers from CyP-D knock-out mice are extremely resistant to Ca
2+
-
induced opening of the mPTP (Basso et al, 2005), pointing to an important role for 
this protein in mPTP formation.  In 2008 it was discovered that PiC binds to CyP-D 
in a cyclosporine-sensitive manner (cyclosporine interacts with CyP-D, preventing 
pore formation), and that PiC can also associate with ANT – suggesting that PiC may 
also play a role in mPTP formation (Leung et al, 2008).  The modulatory (i.e. not 
essential) role for the ANT arises from the evidence that livers from mice without 
ANT1 or ANT2 still present a permeability transition (Kokoszka et al, 2004).  It is 
important to note, however, that only nucleotides transported by ANT (i.e. ATP and 
ADP) can inhibit mPTP opening, implicating ANT in regulation of the pore 
(Halestrap et al, 1997; the role of ANT is reviewed in Leung & Halestrap, 2008).  
 VDAC was originally proposed to be an important part of the mPTP by Zoratti & 
Szabo in 1994, as it had been co-purified with ANT.  The role of VDAC is 
controversial though, as more recently is has been shown that mitochondria from 
VDAC-null mice exhibited a Ca
2+ 
- and oxidative stress-inducible permeability 
transition comparable to that observed in mitochondria from wild-type mice (Baines 
et al, 2007). 
However, in comparison to this role in the initiation of cell death it has also been 
suggested that transient opening of this channel can have a cytoprotective effect 
(Hausenloy et al, 2004).  Despite this, the mPTP appears to play a key role in 
regulation of ischaemia/reperfusion injury, and provides a good target for 
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cardioprotective therapies – and the potential modulation of the mPTP by the KATP 
channel, or BKCa channel, provides an exciting area of research.    
It is proposed that during oxidative stress, while the energy state still favours 
apoptosis, the mPTP opens allowing influx of water and solutes into the 
mitochondria, increasing matrix volume and rupturing the outer membrane.  This 
allows the release of cytochrome c from the intermembrane space, formation of the 
apoptosome (a complex of cytochrome c, APAF-1 and pro-caspase-9) and initiation 
of the caspase cascade – resulting in apoptotic cell death (see Figure 1.3).  As 
oxidative stress increases, necrosis is favoured.  Opening of the mPTP leads to ATP 
hydrolysis, so worsening energy metabolism and causing further Ca
2+
 deregulation.  
This feeds back to the mitochondria – initiating more mPTP opening and eventual 
loss of energy and Ca
2+
 regulation, culminating in necrosis (see Figure 1.3).  
However, although prolonged exposure is ultimately damaging, ischaemia can also 
have a beneficial effect.  
1.4. Ischaemia as a trigger of cardioprotection   
It is now well accepted that a brief period of ischaemia and reperfusion (I/R) can 
protect against a subsequent, prolonged I/R.  This phenomenon, termed ischaemic 
preconditioning, has been demonstrated in various models including swine (Schott et 
al, 1990) and dog (Murry et al, 1986), as well as several in vitro models such as 
isolated rabbit cardiomyocytes (Armstrong et al, 1994).  There is also evidence 
suggesting that ischaemic preconditioning can be beneficial when used in a clinical 
setting with coronary artery bypass graft surgery (CABG).  For example, Wu et al 
(2002) found that brief periods of ischaemia before CABG, in patients with 3 vessel 
disease, significantly reduced the occurrence of ventricular fibrillation and 
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tachycardia after the operation.  The same group (Laurikka et al, 2002) used the 
same preconditioning protocol in patients with 2 vessel disease and found that, 
following CABG, myocardial enzyme release was attenuated, heart rate was 
stabilised and recovery of stroke volume was increased compared to the control 
group.   
The ischaemic preconditioning phenomenon first described by Murry et al (1986) is 
now described as “classical”, or “early phase” preconditioning.  This form of 
preconditioning refers to transient beneficial effects (1-2 hours) that develop within 
minutes of the cardioprotective stimulus, e.g. a brief period of sublethal ischaemia 
(see figure 1.4).  It involves rapid modulation of pre-existing proteins within the cell, 
such as activation of GPCRs, protein kinases and ion channels, and provides 
protection in many models against ischaemia/reperfusion injury (for reviews see 
Sanada & Kitakaze, 2004; Bolli, 2007).   
In 1993 two separate groups (Kuzuya et al, 1993; Marber et al, 1993) reported that 
some effects of myocardial protection could still be observed 24 hours after the 
initial preconditioning stimulus.  This is now termed “late phase” or “second 
window” preconditioning, and describes long lasting effects (peak protection at 24-
72 hours) that develop from 6 hours of the preconditioning stimulus.  As the longer 
time span would suggest, the late phase of preconditioning arises from different 
signal transduction mechanisms to the early phase – although some commonalities 
do occur.  A key feature of late phase preconditioning is up-regulation of 
cardioprotective genes and the synthesis of new proteins, e.g. inducible nitric oxide 
synthase (iNOS), which is a well known mediator of late phase preconditioning and 
is reported to provide protection via inhibition of mitochondrial swelling and 
inhibition of the mPTP (West et al, 2008).  It has also been reported that anti-
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apoptotic, prosurvival genes are also “switched on” and proteins synthesised during 
the late phase of preconditioning (Stein et al, 2007) – further strengthening the role 
of apoptosis in ischaemia/reperfusion injury.  These two forms of ischaemic 
preconditioning can both reduce infarct size in various animal models (see Yellon & 
Downey, 2003, for comprehensive review), but in mice the early phase is reported to 
be more potent (Guo et al, 1998).  However, the late phase of ischaemic 
preconditioning can also provide protection against myocardial stunning in conscious 
rabbits (Dawn et al, 1999).  Figure 1.4 provides a basic outline of the phases 
involved in ischaemia/reperfusion injury and types of cardioprotection.  The duration 
of ischaemia and reperfusion varies between experimental models, but the general 
outcomes are highlighted in the text. 
Ischaemia/reperfusion
Pre-conditioning
< 2h = early phase
24-72h = late phase
Post-conditioning
I/R INJURY:
Myocardial stunning
Hibernation
Cell death
Contractile dysfunction
Arrhythmia
Myocardial infarction
CARDIOPROTECTION:
Reduced cell death
Improved recovery of function
Reduced infarct size
 
Figure 1.4: Graphical representation of ischaemia/reperfusion and 
pre/postconditioning.  Ischaemia/reperfusion leads to ischaemia/reperfusion injury (I/R 
injury), which can be attenuated by ischaemic pre- or postconditioning.  Areas of blue 
indicate ischaemia, red indicated normal perfusion.  Diagram adapted from Ferdinandy et al, 
2007. 
Both the early and late phases of ischaemic preconditioning rely on signal 
transduction pathways to link the initial trigger of cardioprotection with the overall 
effectors, or mediators.  During the preconditioning period of ischaemia autacoid 
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triggers such as adenosine (Headrick, 1996), opioid peptides (Pan et al, 2000), 
bradykinin (Romano et al, 2004) and catecholamines (Schömig, 1990) are released 
from the myocardial tissue.  These are thought to stimulate specific G protein-
coupled receptors (GPCRs) and protein kinases, which culminate in activation of 
mediators such as the mitochondrial ATP-dependent potassium (KATP) channel (for 
examples see Peart & Gross, 2003; Uchiyama et al, 2003).  The precise signalling 
pathways involved in ischaemic preconditioning are still under debate, but 
extracellular signal-regulated kinase 1/2 (ERK1/2), protein kinase C (PKC), cAMP-
dependent protein kinase (PKA), cGMP-dependant protein kinase (PKG), p38 
mitogen-activated protein kinase (p38 MAPK) and nitric oxide (NO) all have well 
reported roles (Hausenloy & Yellon, 2006) (see Figure 1.5). 
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Figure 1.5: Proposed series of events following the release of autacoids during 
ischaemic preconditioning.  Autacoids are released by myocardial cells and activate 
specific GPCR subtypes.  The receptors bind to G proteins, which once activated can 
stimulate protein kinases and other effectors – culminating in activation of the mitochondrial 
KATP channel, ROS regulation and reduced mitochondrial permeability transition. 
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The MEK1/2-ERK1/2 and PI3K-PKB signalling pathways are key players in the 
“RISK” (Reperfusion Injury Salvage Kinase) pathway (Hausenloy & Yellon, 2004).  
Both of these pathways have been shown to be activated at the time of reperfusion 
following pharmacological preconditioning (Yang et al, 2004a & 2004b), leading to 
recruitment of downstream anti-apoptotic molecules (see Figure 1.6).   
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ERK1/2
PI3K
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ACTIVATION OF DOWNSTREAM
CELL SURVIVAL EFFECTORS
 
Figure 1.6: The basic steps leading to activation of ERK1/2 and PKB.  (See main body of 
text for more detailed description.) 
 
For initiation of the MEK/ERK1/2 pathway GTP-bound Ras recruits Raf to the 
plasma membrane, and then phosphorylates Raf.  Active Raf then phosphorylates 
MAPK/ERK kinase 1 (MEK1) and MEK2.  MEK1/2 phosphorylation leads to 
phosphorylation of ERK1/2, and then ERK1/2 can activate downstream targets.  One 
anti-apoptotic pathway mediated by ERK1/2 activation is through the downstream 
activation of the protein kinase p90 ribosomal S6 kinase (p90RSK) (Herrera & 
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Sebolt-Leopold, 2002).  p90RSK phosphorylates and inactivates the pro-apoptotic 
protein BAD, so inhibiting BAD-mediated cytochrome-c release and caspase 
activation (Downward, 1999).  
The role of ERK1/2 in preconditioning and postconditioning is clear.  For example, it 
has been shown that ERK1/2 phosphorylation is increased following a 
preconditioning stimulus in rat hearts in vitro (Hausenloy et al, 2005 & 2005a), and 
also in rat hearts in vivo – where a role for ERK1/2 was described in ischaemic 
preconditioning and preconditioning mediated by the δ-opioid receptor (Fryer et al, 
2001).  ERK1/2 phosphorylation is also increased in post-conditioned in vivo pig 
hearts (Schwartz & Lagranha, 2006) – pointing to recruitment of similar pathways 
for pre- and postconditioning.  In fact, it has been reported that it is the first few 
minutes of reperfusion following the major ischaemic insult that is critical for both 
pre- and postconditioning (Hausenloy & Yellon, 2007a).  It is known that activation 
of the adenosine A1 receptor leads to ERK1/2 phosphorylation, but there is variation 
regarding the role of ERK1/2 in adenosine receptor-mediated cardioprotection.  It 
was shown that the anti-apoptotic effect of adenosine in neonatal rat cardiomyocytes 
was mediated by the A1 and A3 receptors, and dependent on MEK/ERK1/2 activation 
(Germack & Dickenson, 2005).  However, a study with isolated rat ventricle strips 
found that inhibition of MEK did not affect adenosine A1, A2A or A3 receptor-
mediated preconditioning, but did attenuate hypoxic preconditioning (Button et al, 
2005).  ERK1/2 is also proposed to be involved in mitoKATP channel signalling in 
isolated rabbit hearts (Naitoh et al, 2006).   
The PI3K/PKB pathway is initiated by phosphorylation of PIP2 by PI3K, generating 
PIP3.  PIP3 recruits cytoplasmic PKB and PDK to the plasma membrane, where PDK 
activates PKB.  Activated PKB then redistributes to the mitochondria (Miyamoto et 
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al, 2008) or nucleus (Shiraishi et al, 2004), and activates anti-apoptotic pathways.  
One such pathway is via inhibition of BAD (Datta et al, 1997), which is a 
mechanism triggered by both the PI3K/PKB and MEK/ERK1/2 pathways.  PKB is 
also proposed to enhance the association of hexokinase with VDAC at the outer 
mitochondrial membrane, so preserving mitochondrial integrity and inhibiting 
opening of the mPTP (Gottlob et al, 2001).  It has been shown that PDK1 (and, 
therefore, phosphorylation of PKB) is essential for ischaemic preconditioning, as the 
beneficial effect of ischaemic preconditioning is lost in hearts and cell models from 
PDK1-deficient mice (Budas et al, 2006).  Phosphorylation of PKB is increased in 
various models of cardioprotection, including preconditioning of in vitro rat and 
rabbit hearts (Hausenloy et al, 2005 & 2005a; Solenkova et al, 2005), and 
postconditioning of in vivo pig hearts (Schwartz & Lagranha, 2006).  Increased 
phosphorylation of PKB has also been described in the protection of isolated rat 
hearts by ischaemic postconditioning and low-pressure reperfusion, where inhibition 
of the mPTP is the proposed target (Bopassa et al, 2006).  As with ERK1/2, 
activation of PKB via opening of the mitoKATP channel has also been reported 
(Ahmad et al, 2006), and the role of PKB phosphorylation in adenosine receptor-
mediated cardioprotection is poorly understood.  Qin et al, (2003) discovered that 
adenosine triggered preconditioning in isolated rabbit hearts by a PI3K-independent 
pathway, but another report (Solenkova et al, 2006), claimed that endogenous 
adenosine protects isolated rabbit hearts through phosphorylation of PKB during the 
early stage of reperfusion.  In neonatal rat hearts, it was shown that PKB 
phosphorylation was involved in adenosine A1 and A3 receptor-mediated signalling, 
but not in A1 and A3 receptor-mediated cardioprotection (Germack et al, 2004).   
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It is reported that cross-talk occurs between the MEK1/2-ERK1/2 and PI3K-PKB 
pathways, and activation of both at the start of reperfusion is necessary to exert the 
protective preconditioning effect (Hausenloy et al, 2004; Solenkova et al, 2006).  
Taken as a whole, a role for the MEK/ERK1/2 and PI3K/PKB pathways in anti-
apoptotic and cardioprotective signalling is clear, but further work is necessary to 
elucidate the role of these pathways in adenosine receptor-mediated cardioprotection.   
The PI3K/PKB pathway can also activate endothelial nitric oxide synthesase 
(eNOS), which synthesises NO.  NO has many roles in the cardiovascular system, 
including activation of the mitoKATP channel.  NO activates soluble guanylyl cyclase, 
which then produces cGMP from GTP.  cGMP then activates PKG, which 
phosphorylates a target on the outer mitochondrial membrane and (via an unknown 
intermediate step) activates PKC and consequentially the KATP channel (Cuong et al, 
2006; Downey et al, 2008). 
During ischaemia it is thought that there is in increase in cAMP which activates PKA 
– however the result of such activation is debatable.  PKA activation prior to 
ischaemia has been reported to reduce infarct size in dogs (Sanada et al, 2004), but 
conversely blockade of PKA prior to ischaemia is reported to reduce infarct size and 
improve post-ischaemic recovery in isolated rat hearts (Makaula et al, 2005).   
There is a large body of evidence suggesting PKC as a mediator of cardioprotection 
triggered by ischaemia and pharmacological agents, such as adenosine and the 
volatile anaesthetic isoflurane (Liu et al, 1999; Ludwig et al, 2004; Okada et al, 
2005).  There are ten isoforms of PKC, with the novel, Ca
2+
-independent PKCδ and 
PKCε being dominant in murine heart with regards to protein expression and activity 
(Schreiber et al, 2001).  However there are conflicting reports regarding the 
28 
 
expression of the different PKC isoforms; for example, in human ventricle it is 
reported that the Ca
2+
-dependent PKCα, PKCβI and PKCβII are dominant, with 
PKCδ and PKCδ mainly expressed in the atria and PKCε and PKCλ expressed 
equally in both regions (Simonis et al, 2007).  Therefore data from different animal 
models must be interpreted cautiously.  Despite these discrepancies, PKCε is 
reported to be involved in cardioprotective signalling in several models as diverse as 
rabbit cardiomyocytes (Liu et al, 1999) and human myocardium (Sivaraman et al, 
2009).  Following a trigger, PKCε is activated and translocates within the cell to 
activate downstream effectors such the mitoKATP channel and the mPTP – where it 
exerts a protective effect by activation or inhibition of these proteins (for review see 
Budas & Mochly-Rosen, 2007).  In contrast to the role for PKCε as a critical 
mediator of ischaemic pre- and postconditioning (Zatta et al, 2006), PKCδ has a role 
in mediating ischaemia/reperfusion-induced apoptosis Liu et al, 1999) – and it has 
been shown that inhibition of PKCδ at the time of reperfusion can improve recovery 
of function and reduce infarct size in murine hearts (Inagaki et al, 2003). 
Overall, there is much evidence suggesting that protein kinases have an essential role 
in regulation of cardioprotective signalling, and due to the timing of activation it has 
been proposed that the RISK pathway has an important role in preconditioning and 
postconditioning (Hausenloy et al, 2005), although the exact mechanisms involved 
are unknown. 
Ischaemic postconditioning is a more recently discovered cardioprotective 
phenomena (Zhao et al, 2003).  This consists of brief, sublethal cycles of 
ischaemia/reperfusion after the prolonged ischaemic attack, and has since been 
observed in various experimental models, e.g. isolated rabbit hearts (Pinheiro et al, 
2009) and isolated rat hearts (Penna et al, 2009). 
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Clarification of the signalling pathways involved in ischaemic pre- and 
postconditioning would provide scientists with potential targets for pharmacological 
treatments, so gaining the beneficial effects observed from these phenomena without 
the complexity of inducing ischaemia in patients.  The pathways involved may be 
intricate, but it cannot be denied that GPCRs play an essential part in triggering the 
signal transduction pathways that eventually lead to cardioprotection.   
1.5. G protein-coupled receptors 
Currently, over 30% of prescription drugs target one or more GPCR, and it is thought 
that many more act through GPCRs indirectly (Vaidehi et al, 2009).  GPCRs are a 
super-family of cell surface receptors characterised by seven trans-membrane 
spanning domains (7TM α-helices) with a long-chain lipid anchor to strengthen 
membrane association, an intracellular amino terminal and an extracellular carboxyl 
terminal (see Figure 1.7, page 30).  They are widely distributed throughout 
mammalian cells and tissues, and are responsible for mediating intracellular 
responses to a range of extracellular signals.  The binding of a ligand to the receptor 
sets off a cascade of events involving second messengers such as cyclic nucleotides, 
IP3 and Ca
2+
. 
The structure of the light-sensitive rhodopsin receptor was the first to be determined 
(Palczewski et al, 2000), and the crystalline structure of this receptor provided a 
basis for understanding the structure and function of further GPCRs.  The rhodopsin-
like/Class A receptors form the largest subgroup of GPCRs, and they can be 
activated by an extensive range of ligands such as light (rhodopsin receptor), 
peptides (e.g. opioid receptors) and hormones (e.g. follicle stimulating hormone 
receptor).      
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Figure 1.7: Schematic diagram showing the basic structure of a Class A GPCR.  Class 
A GPCRs are activated when a ligand interacts with the 7TM domain, initiating a cascade of 
events culminating in an intracellular response. 
 
Receptor activation occurs when a ligand binds to the receptor, creating a 
conformational change (see Figure 1.8 for overview, page 31).  This allows the 
receptor to act as a guanine nucleotide exchange factor (GEF), catalysing the 
exchange of Gα-bound GDP for GTP.  The heterotrimeric G protein dissociates into 
Gα-GTP and Gβγ subunits which then act upon downstream targets.  The Gβγ 
subunit is generally thought to remain as a tightly associated heterodimer throughout 
the signalling process, however there is an exception to this rule.  It has been shown 
that a Gβ subunit exists in the brain and retina that only associates with the γ-like 
domain of a regulator of G protein signalling (RGS), instead of a traditional Gγ 
protein (Cabrera et al, 1998; Witherow et al, 2000).   Once dissociated from the Gα 
subunit, Gβγ is able to activate signalling enzymes such as phospholipase A2 (PLA2), 
or directly act upon ion channels such as L-type Ca
2+ 
channels and G protein-coupled 
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inward rectifying K
+
 channels (Jelsema & Axelrod, 1987; Viard, 1999; Hommers et 
al, 2003).   
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Figure 1.8: Conformational changes during GPCR activation.  (1) In the unoccupied, 
resting state the inactive heterotrimeric G protein is bound to GDP.  (2) Upon ligand binding 
a conformational change occurs in the receptor, exposing a catalytic component that 
exchanges GDP for GTP.  (3) The active Gα-GTP subunit dissociates from the membrane-
bound Gβγ subunit and both trigger downstream effectors and signalling pathways.  (4) The 
signal is terminated by hydrolysis of GTP to GDP by intrinsic GTPase activity of the α-
subunit, and the receptor/G protein complex returns to resting state. 
 
GPCRs are further classified by the associated G protein α subunit (see Figure 1.9, 
page 32).   
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Figure 1.9: Signalling pathways mediated by the main classes of G protein.  Gαs and Gαi 
proteins have respective stimulatory and inhibitory effects on adenylate cyclase and its 
downstream effectors.  Gαq/11 protein activates phospholipase C, leading to protein kinase C 
activation and calcium signalling.  Gα12/13 proteins act upon guanine nucleotide exchange 
factors of the Rho family. 
The main subtypes are Gαs, Gαi/o and Gαq/11.  Gαs proteins are so named because of 
the stimulatory effect of the subunit on the enzyme adenylate cyclase, which 
produces second messenger cAMP.  Gαs proteins are selectively activated by cholera 
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toxin.  The Gαi/o protein subunit, on the other hand, has an inhibitory effect on 
adenylate cyclase, and is sensitive to pertussis toxin.  The Gαq,11 proteins affect the 
phosphoinositide system by activating phospholipase C-β (PLCβ), which cleaves 
phosphatidylinositol bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 
trisphosphate (IP3).  DAG then activates protein kinase C (PKC) while IP3 stimulates 
the release of intracellular calcium.  These proteins are also distinguished from Gαs 
and Gαi/o proteins as they are insensitive to both cholera toxin and pertussis toxin.  
The G protein-mediated signal is terminated by hydrolysis of GTP to GDP and re-
association of the inactive Gαβγ heterotrimer.  The Gα subunit has innate GTPase 
activity, but this does not always terminate the signal fast enough.  Regulators of G 
protein signalling (RGS) proteins enhance the speed of hydrolysis by acting as 
GTPase-activating proteins (GAPs), this is possible as they contain a RGS domain 
that binds to the Gα subunit and stimulates GTPase activity (for review see 
Hendriks-Balk et al, 2008).  
There are many cardioprotective GPCRs expressed in the heart, including adenosine 
receptors, the signalling mechanisms of which are of interest with regard to finding 
pharmacological targets to protect against myocardial injury.      
1.6. Adenosine receptors 
Adenosine is a purine nucleotide released from myocardial tissue during periods of 
metabolic stress.  It equilibrates the balance between cellular energy supply and 
demand, as well as having important roles in normal physiological regulation.  
Research has shown that adenosine is released during ischaemia or 
ischaemia/reperfusion, and it has been reported that the extracellular concentration of 
adenosine in the body can increase 100-fold up to 10 µM during hypoxia or 
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ischaemia (Schulte & Fredholme, 2003).  This endogenous adenosine then exerts a  
cardioprotective effect against ischaemia/reperfusion-induced injury and cell death 
(Mubagwa & Flameng 2001; Fryer et al, 2002).  
Four adenosine receptors (A1, A2A, A2B and A3) belonging to the GPCR superfamily 
have been cloned and characterised (Fredholm et al, 2001).  The A1 and A3 receptors 
are negatively coupled to adenylate cyclase via pertussis toxin-sensitive Gi/o 
proteins, therefore inhibit cAMP production (Fredholm et al 2001).  It is well known 
that the A1 and A3 receptors are involved in cardioprotection (Mubagwa & Flameng 
2001; Fryer, Auchampach & Gross 2002).  Adenosine A2A and A2B receptors are 
positively coupled to adenylate cyclase via Gs proteins, and have high and low 
affinities for adenosine, respectively.  All four of the adenosine receptor subtypes are 
expressed in the heart (see Auchamp & Bolli, 1999), but the presence of A2A 
receptors on cardiomyocytes is debateable.  Adenosine A2A receptors are widespread 
throughout coronary vessels where activation causes potent vasodilation, but are 
reported to be absent from porcine cardiomyocytes (Hein et al, 2001).  In 2002 it was 
reported that rat ventricular myocytes express A2A receptors, but these receptors are 
not functional as no response was observed from selective agonism (Kilpatrick et al, 
2002).  However, in separate studies functional A2A receptors have been described in 
adult and neonatal rat cardiomyocytes (Xu et al, 1996; Germack & Dickenson, 2004) 
and human atrial myocytes (Hove-Madsen et al, 2006).   
Ischaemic preconditioning reduces infarct size in intact rabbits, and this protection 
has been shown to be abolished by infusion of different non-selective adenosine 
receptor antagonists prior to the preconditioning phase (Liu et al, 1991).  This 
pointed to an important role for adenosine and one or more adenosine receptor 
subtypes in ischaemic preconditioning. This report also progressed on to show that 
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selective antagonism of the A1 receptor blocked the protection afforded by ischaemic 
preconditioning.  Further strengthening the role for the A1 receptor in  
preconditioning, the same group (Thornton et al, 1992) demonstrated that infusion of 
a selective A1 agonist prior to ischaemia reduced infarct size to the same extent as 
ischaemic preconditioning – but an A2A agonist had no effect.  It has also been 
shown that activation of the A1 receptor is an effective trigger of the early and late 
phases of preconditioning in isolated hearts from normal and hypertensive rats 
(Hochhauser et al, 2007); in addition, this report showed that activation of the A3 
receptor was partially effective as a preconditioning trigger, particularly in the late-
phase model.  A place for the A3 receptor in cardioprotection had also been described 
earlier by Auchampach et al (1997), who reported that activation of the A3 receptor 
in conscious rabbits gave a level of protection equivalent to that obtained from 
ischaemic preconditioning.  This report measured the effect of A3 receptor activation 
on both myocardial stunning and infarct size, and claimed protection in both areas, 
interestingly without any hemodynamic changes.  Activation of the A1 receptor 
produces vasodilation, which is undesirable in the clinical setting (Mustafa et al, 
2009).  There are many studies assessing infarct size as a measure of 
cardioprotection, but fewer that look into myocardial function.  One such study 
found that ischaemic preconditioning did not preserve myocardial function in dogs, 
but preconditioning with adenosine did (Phillips & Ko, 2007).  However, this 
protection came at a cost as treatment with adenosine lead to an increased energy 
requirement of the heart and oxygen wasting.   
The timing of pharmacological treatment can also affect the extent of protection 
gained, but findings do vary between models used.  For example, infusion of 
adenosine at the time of reperfusion is effective at reducing infarct size in dogs 
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(Velasco et al, 1991), but no protection was observed in isolated rabbit hearts (Xu et 
al, 2001).  It has been reported that activation of the A2B receptor at the time of 
reperfusion is important for ischaemic preconditioning in rabbit hearts (Kuno et al, 
2007), and also that postconditioning is dependent on activation of the A2B receptor, 
but not A1 or A2A receptors (Philipp et al, 2006).  These data suggest that the A2B 
receptor is the main mediator of postconditioning, but the protective effect of 
ischaemic postconditioning is lost in A1 receptor knock-out mice, suggesting an 
additional role for the A1 receptor (Xi et al, 2008).  Interestingly, the protection 
afforded by ischaemic preconditioning was absent in A2B receptor knock-out mice – 
but mice lacking the A1, A2A or A3 receptor had a preserved response (Eckle et al, 
2007).  It has been proposed that the release of adenosine during ischaemic 
preconditioning triggers activation of the A1 and A3 receptors, which (via a Gi 
protein and PKC-dependent pathway) activate the A2B receptor.  The A2B receptor 
then mediates ischaemic preconditioning by targeting effecter proteins such as the 
KATP channel and the mPTP (Cohen & Downey, 2008). 
There is a clear role for the adenosine A1 and possibly A2B and A3 receptors in 
cardioprotection, however, the role of the A2A receptor remains controversial. For 
example, in anesthetized rabbits there is evidence for and against adenosine A2A 
receptor-mediated protection.  Phillip et al (2006) described that postconditioning 
could be blocked with an antagonist at the A2B receptor, but not the A2A or A1 
receptors.  Alternatively, Boucher et al (2004) described that activation of the A2A 
receptor 5 minutes prior to (but not 5 minutes after) the onset of reperfusion 
successfully reduced infarct size.      
Understanding the signal transduction mechanisms involved in adenosine receptor-
mediated cardioprotection is an area of intense investigation, especially since 
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adenosine has shown promise in clinical trials (Bolli et al 2004).  However, further 
work is needed before further clinical trials are considered.  The Acute Myocardial 
Infarction Study of Adenosine Trials (AMISTAD and AMISTAD II) showed that 
adenosine was effective at reducing infarct size in humans, but there was no 
significant improvement of clinical outcome (Mahaffey et al, 1999; Ross et al, 
2005).  From the diverse range of data obtained from animal models it was perhaps 
unwise to invest such a large amount of time and money into clinical trials at this 
stage.   
As mentioned previously, stimulation of the adenosine A1 receptor has been found to 
lead to activation of signalling pathways involving several different protein kinases.  
PKC (Henry et al, 1996), ERK1/2 (Germack & Dickenson, 2005) and p38 MAPK 
(Dana et al, 2000) have all been implicated, and another commonly described feature 
of adenosine A1 receptor-mediated cardioprotection is the mitochondrial KATP 
channel (e.g. Van Winkle et al, 1994; Heurteaux et al, 1995; Baxter & Yellon, 1999).  
The KATP channel is one of several cytoprotective channels expressed in the inner 
mitochondrial membrane, and has a well reported role in cardioprotection.  More 
recently, however, a large conductance calcium-activated potassium channel (BKCa 
channel) located to the inner mitochondrial membrane has also been implicated in 
cardioprotection. 
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1.7. Large conductance calcium-activated potassium channels 
There are two types of BKCa channel, one found on the inner mitochondrial 
membrane and the other on the cytoplasmic membrane.  Mitochondrial BKCa 
channels are abundant in the brain and cardiac tissue, cytoplasmic BKCa channels are 
ubiquitously expressed throughout vascular beds in the membranes of smooth muscle 
cells (Korovkina & England, 2002).  The exact structure of the BKCa channel is 
currently under debate, but it is thought that the channel consists of a tetramer of 
pore-forming α-subunits that alone constitute a fully functional channel (see Figure 
1.10, page 39), with associated modulatory β-subunits (Yusifov et al, 2008).  The β1 
subunit is expressed in mammalian cardiac mitochondria (Ohya et al, 2005), and the 
β4 subunit is highly expressed throughout brain mitochondria (Piwonska et al, 2008) 
– however, although it is predominantly located to the brain, the β4 subunit has also 
been detected in cardiac tissue (Poulsen et al, 2009). 
The α-subunits are proposed to form a C-terminal Ca2+ bowl, containing two Ca2+-
sensing domains (RCK, regulators of the conductance of potassium, domains), with 
the voltage-sensing domain located on the external side of the channel (Quin et al, 
2006) (see Figure 1.11, page 39).   
Xu et al (2002) first discovered the presence of this channel on the inner 
mitochondrial membrane of guinea pig ventricular cells, and reported that 
pharmacological activation of this channel provided protection against ischaemic 
injury.  Since then, mitochondrial BKCa channels have been implicated in 
cardioprotective mechanisms in several different models including anesthetized dogs 
and isolated murine hearts (Shintani et al, 2004; Wang et al, 2004).     
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Figure 1.10: The BKCa channel is formed from a tetramer of α-subunits (dark blue).  
Each subunit consists of seven membrane spanning domains (see highlighted light blue 
section). 
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Figure 1.11: Proposed structure of the BKCa channel subunits.  Each α-subunit (dark 
blue) has an internal Ca
2+
 sensing bowl and an external voltage sensing domain, and a pore is 
formed between the seventh and eight membrane spanning domains.  One auxiliary β-
subunit (light blue) can associate with the N terminal of an α-subunit.  
 
On separate occasions Cao’s group used rat ventricular myocytes and isolated 
perfused rat hearts to  elaborate on the role of the mitochondrial BKCa channel, and 
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reported that this channel is responsible for triggering cardioprotection of ischaemic 
preconditioning (Cao et al, 2005a) and cardioprotection mediated by the κ-opioid 
receptor (Cao et al, 2005).  In the latter study it was also deduced that PKC 
activation occurs upstream of the mitochondrial BKCa channel, and activation of the 
mitochondrial BKCa channel is proposed to lead to inhibition of the mPTP (Cao et al, 
2005; Cheng et al, 2008).  Several other studies have also implicated protein kinases 
in the signal transduction pathways leading to mitochondrial BKCa channel 
activation.  In 2007, Gao et al reported that the cardioprotective isoflavone puerarin 
provides protection against ischaemia/reperfusion in isolated perfused rat hearts by 
activation of PKC and the mitochondrial BKCa channel.  However, Sato et al (2005) 
claimed that activation of PKA enhanced NS1619 (BKCa channel opener)-induced 
flavoprotein oxidation, suggesting that a mechanistic link is present between the two 
signal transducers.  However, no such augmentation was observed with PKC and the 
BKCa channel.  Redel et al (2008) also found that PKA was involved in signal 
transduction leading up to BKCa channel activation, in this case in anaesthetic-
induced preconditioning with desflurane.  Activation of the BKCa channel is involved 
in preconditioning triggered by a variety of pharmacological agents including tumour 
necrosis factor-α, estradiol, the phosphodiesterase type 5 inhibitor sildenafil and the 
phosphodiesterase type 3 inhibitor cilostazol (Gao et al, 2005; Ohya et al, 2005; 
Wang et al, 2008; Fukasawa et al, 2008), and GPCR agonists such as (-)-U-50488 
and adrenomedullin (Cao et al, 2005; Nishida et al, 2008).  However, to date, the 
role of the BKCa channel in adenosine receptor-mediated signalling has yet to be 
investigated.       
Overall, in simple terms, it can be presumed that pre- and postconditioning are 
triggered by stimulation of GPCRs, which leads to recruitment of cell survival 
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protein kinases, and culminates in activation of cytoprotective ion channels.  
However, the precise mechanisms are still under debate.  Any information that could 
lead to elucidation of cardioprotective signalling would help in the search for 
effective pharmacological targets against ischaemia and ischaemia/reperfusion 
injury.  
1.8. H9c2 cells and rat ventricle strips – models for studies into 
cardioprotection  
 
The H9c2 cell line is derived from embryonic rat heart tissue (Kimes & Brandt, 
1976), and is increasingly used as an in vitro model of cardiac tissue for studies into 
cardioprotection as these cells display similar morphological, electrophysiological 
and biochemical properties to primary cardiac cells (Hescheler et al, 1991).  It has 
previously been shown that adenosine can protect against simulated ischaemia in 
H9c2 cells, although the subtype of adenosine receptor involved in such 
preconditioning and the type of cell death triggered by ischaemia were not reported 
(Nagarkitti & Sha’afi, 1998).   
H9c2 cells are a useful model for investigating cardiac signal transduction, and also 
for assessing the cardioprotective potential of pharmacological agents from a cell 
viability perspective.  It is always advisable to compare experimental results from 
more than one model as discrepancies often occur between different cell, tissue and 
animal models, so a comparison of data from more than one model gives a more 
rounded perspective and verification of results.  To validate the results obtained from 
H9c2 cells in this report a model using isolated rat right ventricle strips was utilised. 
Rat ventricle strips are a more physiologically relevant model for studies into 
cardioprotection than H9c2 cells, and are reported to exhibit a larger hypoxia-
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induced mechanical impairment than strips from guinea pig or frog ventricles 
(Joseph et al, 2000) – therefore they are ideal for assessing the potential of 
pharmacological agents to protect against hypoxia.  It has been shown that adenosine 
treatment does not provide any benefit to rat ventricle strips during hypoxia (Varela 
et al, 1999), but preconditioning with adenosine and agonists specific to the 
adenosine A1, A2A and A3 receptors significantly increase the return of mechanical 
function during reperfusion (Button et al, 2005).  However, the role of the BKCa 
channel in preconditioning of rat ventricle strips has not been investigated. 
1.9. Aims of this project 
The main aims of this project were: 
1) To establish the functional expression of GPCRs on H9c2 cells, and assess 
the cytoprotective potential of such receptor activation 
2) To investigate the role of the BKCa channel in adenosine A1 receptor-
mediated signalling in H9c2 cells 
3) To validate the data obtained from H9c2 cells and research the role of the 
BKCa channel in adenosine receptor-mediated preconditioning in rat ventricle 
strips 
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2. Methods 
2.1.  Cell Culture 
Rat embryonic cardiomyoblast-derived H9c2 cells (European Collection of Animal 
Cell Cultures, Salisbury, UK) were cultured in 75 cm
2
 flasks in Dulbecco’s Modified 
Eagles Medium (DMEM) supplemented with 10% (v/v) foetal calf serum, 2 mM L-
glutamine and 100 U/ml penicillin/streptomycin.  Cells were maintained in a 
humidified incubator (95% air / 5% CO2, 37°C) and grown to 70-80% confluency to 
avoid differentiation and formation of myotubes.  Typically, cells were sub-cultured 
with a 1:5 split using trypsin (0.05% w/v)/EDTA (0.02% w/v).  Cells for functional 
receptor expression assays were grown in 24 well plates (Sarstedt), cells for LDH 
assay were grown in 96 well plates (Sarstedt) and cells for caspase-3 analysis and 
western blot were grown in 60mm culture dishes (Greiner Bio-One). 
2.2. Functional Expression of GPCRs: 
i)  Measurement of cAMP accumulation   
Confluent H9c2 cells were incubated with 500 μl serum-free DMEM and 2 µCi [3H]-
adenine for 2 hours, then washed twice with Hank’s Balanced Salt Solution (HBSS) 
to remove excess radioactivity.  Cells were treated with the phosphodiesterase 
inhibitor rolipram (10 μM in 500 μl serum-free DMEM) and incubated for 15 
minutes in a humidified incubator (95% air / 5% CO2, 37ºC).  Agonists were then 
added (1:10 dilution) and incubated for a further 15 minutes.  When assessing Gi-
coupled receptor activity, the agonists were added 5 minutes prior to a 10 minute 
incubation period with forskolin (10 µM).  If required, cells were pre-treated with 
antagonists for 15 minutes prior to addition of rolipram.  The experiments were 
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terminated by exchanging the media for 500 μl trichloroacetic acid (5% w/v) then 
plates were wrapped in foil and stored at -20ºC. 
Samples were purified by gravitational column chromatography.  Dowex columns 
were pre-washed with 5 ml HCl (1 M) and 20 ml distilled water, alumina columns 
were pre-washed with 20 ml imidazole (0.1 M).  Well content was transferred to the 
dowex columns and washed through with 3 ml distilled water.  The dowex columns 
were then placed on top of the alumina columns and 4 ml distilled water washed 
through both sets.  5 ml HCl (1 M) and 20 ml distilled water was then used to wash 
the dowex columns only, while 5 ml imidazole (0.1 M) was drained through the 
alumina columns and collected in scintillation vials.  The cAMP had now been eluted 
from the alumina columns so they were washed with 20 ml imidazole (0.1 M).  To 
the vials, 0.5 ml HCl (1 M) and 10 ml liquid scintillant was added (Packard 
Biosciences).  Vials were shaken and activity read using a liquid scintillation counter 
(Packard Tri-Carb Liquid Scintillation Analyser).  For reference, see Cordeaux et al 
(2000). 
 ii)   Inositol trisphosphate Assay 
Confluent H9c2 cells were pre-labelled with 3 μCi [3H] myo-inositol in 500 μl 
serum-free DMEM for 24 hours.  Excess radioactivity was then removed by two 
washes with HBSS, and then cells were incubated with LiCl (20 mM) in 500 μl 
serum-free DMEM for 30 minutes in a humidified incubator (95% air / 5% CO2, 
37ºC).  Without removing the LiCl the cells were further incubated with Gq agonist 
for 30 minutes (1:10 dilution).  Reactions were stopped by replacing the media with 
1 ml termination mix (6 ml concentrated HCl in 500 ml dH2O added to 500 ml 
methanol; pH 2-3). 
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Samples were purified by anion-exchange chromatography.  HCl (10 ml; 1 M) was 
washed through the columns followed by 20 ml distilled water.  Samples were then 
added to 4 ml neutralising solution (0.5 M NaOH, 25 mM Tris; pH 7) and run 
through the columns; 20 ml distilled water followed.  10 ml of ammonium formate 
(25 mM) was drained through then the columns were placed above scintillation vials.  
3 ml HCl (1 M) was run through into the vials then 10 ml liquid scintillant was added 
before reading the radioactivity using a liquid scintillation counter (Packard Tri-Carb 
Liquid Scintillation Analyser).  For reference, see White et al (1992). 
 
2.3.  Protection against hypoxia- and hypoxia/reoxygenation-induced 
cell death: Experimental protocol 
80% confluent H9c2 cells in glucose and serum-free DMEM were exposed to 
hypoxia (5% CO2/0.5% O2; 37°C) for 6 hours (NB. this time varied for time-course 
experiments) before performance of the appropriate cell viability assay.  Normoxic 
incubation was used for controls.   
Where pharmacological preconditioning was required, cells were incubated with 
GPCR agonist or potassium channel opener in 200 μl (when using microplates) / 2 
ml (when using culture dishes) serum-free DMEM  for 30 minutes; this medium was 
then discarded and replaced with 200 μl / 3 ml glucose and serum-free DMEM for 
the hypoxic/normoxic incubation.  When required, cells were also treated with 
antagonist or potassium channel blocker for 15 minutes prior to the addition of 
agonist or channel opener.   
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For hypoxia-reoxygenation experiments, cells were exposed to hypoxia for 6 hours 
as before, and then reoxygenated for 18 hours in 200 μl / 3 ml DMEM containing 
glucose and 1% serum.  Preconditioning occurred prior to hypoxia, postconditioning 
occurred at the start of reoxygenation – treatment protocol as before (see Figure 2.1 
for summary) 
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i)  MTT Assay 
H9c2 cells were cultured in 96 well flat bottom plates, at a density of 5000 cells/well, 
for 24 hours in fully supplemented DMEM.  Incubations were performed in 200ul 
glucose/serum-free DMEM, then cell viability measured by colorimetric assessment 
of the mitochondrial reduction of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to a coloured formazan product.  Cells were incubated 
for 1 hour (37°C) in 0.5 mg/ml MTT.  Solution was then aspirated away and replaced 
with 100 µl DMSO.  Plates were shaken to solubilise the formazan product then 
absorbance read at 570nm using a standard plate reader (Model 680, Bio-Rad).  
Results expressed as percentage of basal MTT reduction. 
ii)  Lactate dehydrogenase (LDH) Assay 
H9c2 cells were cultured in 96 well flat bottom plates, at a density of 5000 cells/well, 
for 24 hours in fully supplemented DMEM.  Incubations were performed in 200 μl of 
the appropriate medium then cell death measured using the colorimetric CytoTox 
96
®
 Non-Radioactive Cytotoxicity Assay (Promega).  This kit allows LDH release to 
be measured via a coupled chemical reaction that leads to formation of a coloured 
formazan product.  Firstly, LDH released from the cells catalyses the formation of 
pyruvate and NADH from lactate and NAD
+
.  The secondary reaction is catalysed by 
the dehydrogenase enzyme diaphorase (present in the substrate mix), and involves 
the formation of NAD
+
 and a red formazan product from NADH and a tetrazolium 
salt.  LDH release is proportional to the red formazan product, which is measured 
using a standard plate reader (Model 680, Bio-Rad).   
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Plates were centrifuged to compact any cell debris to the bottom of the wells (5 
minutes at 300 g), and then 50 μl of supernatant was transferred to a non-sterile 96 
well plate (“assay plate”; Greiner Bio-One).  A further 60 μl of the supernatant was 
discarded before 10 μl of 10x lysis buffer (9% v/v Triton® X-100, provided with kit) 
was added to the remaining 90 μl.  Following 45 minutes incubation at 37°C, the 
plates were centrifuged for 5 minutes at 300 g.  As before, 50 μl of supernatant was 
added to the assay plate.  Reconstituted assay buffer (50 μl; provided in the kit) was 
added to each well, and then the assay plates were wrapped in foil and agitated for 30 
minutes at room temperature.  To terminate the reactions, 50 μl of stop solution (1 M 
acetic acid, provided with kit) was dispensed into each well; absorbance was then 
read at 490nm.  
LDH release was calculated as a percentage of total LDH, and results are presented 
as LDH release as a percentage of basal release (acquired from untreated controls). 
iii)  Caspase-3 Assay 
Cells were cultured in 60 mm dishes, until confluent, in fully supplemented DMEM.  
Where appropriate, treatments were performed in 2 ml serum-free DMEM, this was 
replaced with 3 ml glucose/serum-free DMEM for the 6 hours incubation in hypoxia 
or normoxia.  When the incubation period was over phosphate buffered saline (PBS) 
was used to wash the cells which were then trypsinised and centrifuged for 10 
minutes at 300 g to obtain a cell pellet.  Supernatant was discarded and pellets were 
stored at -20°C until required for the caspase-3 assay. 
Cell pellets were resuspended in 120 μl lysis buffer (25 mM HEPES, 2.5 mM 
CHAPS, 2.5 mM DTT, pH 7.4) and incubated on ice for 20 minutes.  Lysate was 
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then centrifuged for 10 minutes (4°C, 14000 rcf) and supernatant collected and stored 
on ice.  Supernatant (30 μl) was added to a black microplate (Greiner Bio-One) along 
with 50 μl assay buffer (20 mM HEPES, 5 mM DTT, 0.1% CHAPS, 2 mM EDTA, 
pH 7.4) and 20 μl substrate (0.5 mM, Acetyl-Asp-Glu-Val-Asp-7-Amido-Methyl 
Coumarin).  For blanks, assay buffer replaced supernatant. 
Fluorescence was read over a 2 hour period resulting in a linear relationship between 
time and caspase-3 activity (FLUOstar Optima, BMG Labtech).  In combination with 
the protein assay, caspase-3 activity per minute per μg protein (Ufluo/min/μg) was 
calculated and expressed as percentage of basal activity. 
iv)  DC Lowry Protocol – Protein Assay 
Protein content of samples was measured using the DC Lowry Protocol (reagents 
from the Bio-Rad DC Protein Assay range) using bovine serum albumin standards 
(BSA).  Standards were prepared with 2 mg/ml BSA to produce a calibration curve 
as below (table 2.1), to ensure that the relationship between protein content and 
absorbance was linear. 
Table 2.1: BSA standard curve 
Protein mg/ml μl protein standard μl dH2O
0.0 0 >10
0.2 20 180
0.4 40 160
0.5 50 150
0.8 80 120
1.0 100 100
1.5 150 50
2.0 >10 0  
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5 μl of standards and samples were added to a 96-well flat bottom plate in duplicate.  
25 μl of reagent A’ (comprising of 20 μl Reagent S to 1 ml Reagent A; BioRad) and 
200 μl of Reagent B (BioRad) was added to each well and then plates were covered 
in foil and agitated for 15 minutes.  Absorbance was read at 750nm using a standard 
plate reader (Model 680, Bio-Rad).   
Protein content of the samples was obtained by manipulation of the equation of the 
standard curve; results expressed as μg protein/μl. 
2.4.  Western blot analysis of BKCa channel subunit expression and 
protein kinase phosphorylation 
For the determination of BKCa channel subunit expression isolated mitochondrial, 
cytoplasmic and whole cell protein fractions (isolated by subcellular fractionation, 
see section 2.9) were mixed two parts to one part sample buffer (Cell Signalling 
Technology). For the assessment of protein kinase activation H9c2 cells were 
exposed to the conditions and treatments described previously and stated in the 
figure legends. Following stimulation cell supernatants were removed and the cells 
washed twice with ice-cold PBS and lysed in ice-cold lysis buffer (100 μl; 150 mM 
NaCl, 50 mM Tris.HCl, 5 mM EDTA, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) 
sodium deoxycholate, 0.1% (w/v) SDS (sodium dodecyl sulphate), 1 mM Na3VO4, 1 
mM NaF, 1 mM benzamidine, 0.1 mM phenylmethylsulphonylfluoride (PMSF), 10 
g/ml aprotinin and 5 g/ml leupeptin). Cell lysates were cleared by centrifugation 
(5 minutes; 12,000 g; 4°C), the supernatant collected and mixed two parts to one part 
sample buffer – with an aliquot of the supernatant taken for analysis of protein 
content. Samples were boiled at 95ºC for 5 minutes and thoroughly vortexed to 
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ensure protein denaturation, and then stored at -20°C.  Protein concentration was 
determined using Bio-Rad DC Protein assay as described above and protein samples 
separated by Sodium Dodecyl Sulphate/Polyacrylamide Gel Electrophoresis 
(SDS/PAGE) using a Bio-Rad Mini-Protean II system. 
Equipment was set up according to the manufacturers’ instructions and 20 ml of 12% 
acrylamide solution made per two gels (6.6 ml dH2O, 8.0 ml 30% Acrylamide mix, 
5.0 ml 1.5 M Tris buffer, 200 μl 10% SDS solution, 200 μl 10% ammonium 
persulphate (APS) solution, 20 μl TEMED) – APS and TEMED are responsible for 
initiating gel polymerisation so were added last.  The unpolymerised acrylamide gel 
solution was pipetted between two glass plates held together in the BioRad 
equipment, with a gap at the top being left for dH2O to ensure level setting of the gel.  
Once the gel had set, the water was poured off and replaced with stacking gel (for 
two gels: 4.1 ml dH2O, 1.0 ml 30% Acrylamide mix, 750 μl 1.5 M Tris buffer, 60 μl 
SDS solution, 60 μl APS, 6 μl TEMED) and a plastic comb to form wells.  The 
equipment was placed into the lower buffer chamber with electrophoresis buffer 
(24.8 mM Tris base, 192 mM Glycine, 3.5 mM SDS), ensuring that the buffer did not 
leak from between the two gels.  Once the stacking gels had set the combs were 
removed and samples were loaded into the wells (20-30 μg/well depending on target 
protein).  The circuit was then run for 45 minutes at 200 V. 
Separated proteins were transferred to nitrocellulose membranes using a Bio-Rad 
Trans-Blot system (1 hour at 100 V in 25 mM Tris base, 192 mM glycine and 20% 
MeOH). Following transfer, nitrocellulose membranes were stained with Poncea S 
(Sigma) and the appropriate band size identified and cut from the rest of the 
membrane.  The desired strips of membrane were washed with the pH buffer Tris-
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buffered saline (TBS) and blocked for 1 hour at room temperature in blocking buffer 
(TBS, 5% (w/v) skimmed milk powder, 0.1% Tween-20). Membranes were then 
incubated overnight at 4
o
C in blocking buffer with the following primary antibodies: 
cytochrome c (Santa Cruz Biotechnology; 1:500); BKCa channel  subunit (Becton 
Dickinson; 1:250), BKCa channel β4 subunit (Sigma-Aldrich; 1:250), phospho-
specific ERK1/2 (Thr
202
/Tyr
204
; Sigma Aldrich; 1:1000), and phospho-specific PKB 
(Ser
473
; New England Biolabs (U.K.) Ltd; 1:500). The next day the primary antibody 
was removed and the membrane extensively washed three times for 10 minutes in 
TBS/Tween 20. Blots were then incubated for 1 hour at room temperature with the 
appropriate secondary antibody (1:1000) coupled to horseradish peroxidase (DAKO 
Ltd, Cambridge, UK) in blocking buffer. Following removal of the secondary 
antibody, blots were extensively washed as above and developed using the Enhanced 
Chemiluminescence Detection System (Amersham Pharmacia Biotech, Little 
Chalfont, UK) and quantified by densitometry using GeneGenius BioImaging 
System (Syngene, Synoptics Ltd, UK). Replicate samples from each experiment 
were analysed on separate blots using total unphosphorylated ERK1/2 (New England 
Biolabs (U.K.) Ltd; 1:1000) and PKB (New England Biolabs (U.K.) Ltd; 1:1000) 
primary antibodies in order to confirm the uniformity of protein loading. 
2.5.  Subcellular fractionation 
H9c2 cells were grown in 125 cm
2 
culture flasks; to obtain enough protein 3 flasks 
were used per experiment.  Once confluent cells were detached using trypsin and 
then centrifuged for 5 minutes at 300 g.  The supernatant was discarded and the cell 
pellet resuspended in 1 ml PBS and centrifuged again (5 minutes, 300 g).  This 
process was repeated, then the cell pellet was transferred to a Dounce tissue grinder 
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tube (Sigma) kept on ice using a Pasteur pipette and homogenised 10 times with 
grinder A and 10 times with grinder B (Sigma; each time consisting of one clockwise 
rotation of the grinder).  The cell homogenate was resuspended in 500 μl of 
extraction buffer (10 mM HEPES, 1 mM EGTA, 200 mM mannitol, 1 mM sucrose) 
and transferred to a 2 ml centrifuge tube labelled “nucleus”, then centrifuged for 5 
minutes at 300 g (4°C).  The supernatant was transferred to a 2 ml centrifuge tube 
labelled “mitochondria”, with 100 μl being saved as total extract.  The nuclear pellet 
was resuspended in 500 μl of extraction buffer and centrifuged for 10 minutes at 
1000 g (4°C).  The supernatant was again transferred to the mitochondria tube, and 
then the nuclear pellet was discarded.  The mitochondrial fraction was centrifuged 
for 15 minutes at 10,000 g (4°C) then the supernatant was transferred to a 2 ml 
centrifuge labelled “cytoplasm”.  The mitochondrial pellet was resuspended in 500 μl 
extraction buffer and centrifuged for 10 minutes at 10,000 g (4°C).  The supernatant 
was again transferred to the cytoplasmic extract tube and the mitochondrial pellet 
resuspended in 100 μl extraction buffer.  All fractions were then stored at -20°C until 
required. 
2.6.  Right Ventricle Strip Preparation 
All experiments were performed on adult Wistar rats of either sex which were 
executed by cervical dislocation in accordance with the Animals (Scientific 
Procedures) Act 1986.  Hearts were rapidly removed and placed in ice-cold Krebs 
solution (119 mM NaCl, 25 mM NaHCO3, 11.1 mM D-glucose, 4.7 mM KCl, 2.5 
mM CaCl2, 1.2 mM KH2PO4, 1.0 mM MgSO4).  One strip from the right ventricle 
wall (approximately 2 mm x 10 mm) was isolated per heart and then longitudinally 
attached to platinum electrodes and isometric force transducers. The strips were 
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placed under 2 g tension in a tissue bath (Harvard Single Heated Tissue Bath) 
containing 40 ml gassed Krebs (95% O2-5%-CO2, 37°C) and electrically stimulated 
at a frequency of 1 Hz (Ealing Dual Pulse Student Stimulator).  Contractions were 
measured on a chart recorder (Harvard Student Oscillograph).  All strips were 
equilibrated for 40 minutes in gassed Krebs (95% O2-5% CO2, 37°C) before drug 
challenge.  Hypoxia was simulated by replacing the medium with gassed glucose-
free Krebs (95% N2-5% CO2, 37°C).  Normalisation of data controlled for variation 
of data due to ventricle thickness.   
Experimental protocol: 
Following the equilibration period, control strips were exposed to 30 minutes 
oxygenation followed by 30 minutes hypoxia and finally 30 minutes reoxygenation – 
this treatment protocol was previously established by members of my research group, 
therefore deemed appropriate for use with this current project (Button et al, 2005). 
If appropriate, CPA or NS1619 was added to the medium for the final 2 minutes of 
oxygenation.  When using DPCPX, Paxilline or Iberiotoxin the required drug was 
added at the start of oxygenation and remained there for the 30 minutes duration.   
For hypoxic preconditioning, ventricle strips were equilibrated for 40 minutes as  
usual, and then exposed to a 10 minute preconditioning period of hypoxia followed 
by 20 minutes oxygenation, 30 minutes hypoxia and finally 30 minutes 
reoxygenation.  When using iberiotoxin the drug was added after for the final 30 
minutes of the equilibration.  All drugs were washed out following treatment and no 
drugs were present during hypoxia or reoxygenation.  See figure 2.2 for summary. 
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2.7.  Data analysis 
GraphPad Prism 5 was used for all statistical analysis.  The one-way ANOVA 
(analysis of variance) test was used to compare two or more sets of data, with the 
two-way ANOVA being used to compare grouped sets of data.  Tukey's Multiple 
Comparison Post Test was used to further analyse the data to uncover where any 
significance lay.  Significance was classed as p<0.05 and highlighted with an asterix; 
all data is presented as mean ± S.E.M.  
2.8.  Materials 
Acetyl-Asp-Glu-Val-Asp-7-Amido-Methyl Coumarin, acetylcholine, 30% 
acrylamide mix, adenosine, ATP (adenosine triphosphate), baclofen, BSA (bovine 
serum albumin), D-glucose, DPCPX (8-Cyclopentyl-1,3-dipropylxanthine), forskolin, 
histamine, imidazole, isoprenaline, lithium chloride, MRS1220 (N-[9-Chloro-2-(2-
furanyl)[1,2,4]-triazolo[1,5-c]quinazo lin-5-yl]benzene acetamide), noradrenaline, 
NS1619 (1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-
2H-benzimidazol-2-one), PTX (pertussis toxic), rolipram, SDS (sodium dodecyl 
sulphate), TEMED (N,N,N',N'-Tetramethylethylenediamine), TCA (trichloroacetic 
acid), staurosporine, and UTP (uridine triphosphate) were all obtained from Sigma-
Alrich. 
(-)-U-50488 ((±)-U-50488 hydrochloride; trans-(±)-3,4-Dichloro-N-methyl-N-[2-(1-
pyrrolidinyl)cy clohexyl]benzeneacetamide hydrochloride), CGS (CGS 21680 
hydrochloride; 4-[2-[[6-Amino-9-(N-ethyl-b-D-ribofuranuronamidosyl)-9H -purin-2-
yl]amino]ethyl]benzenepropanoic acid hydrochloride), CI-IB-MECA (2-CI-IB-
MECA; 1-[2-Chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9- yl]-1-deoxy-N-
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methyl-b-D-ribofuranuronamide), CPA (N
6
-Cyclopentyladenosine), dobutamine  
(dobutamine hydrochloride; 4-[2-[[3-(4-Hydroxyphenyl)-1-
methylpropyl]aminoethyl-1, 2-benzenediol hydrochloride], iberiotoxin, nor-BNI 
(nor-Binaltorphimine dihydrochloride; 17,17'-(Dicyclopropylmethyl)-6,6',7,7'-6,6'-
imino- 7,7'-binorphinan-3,4',14,14'-tetrol dihydrochloride), paxilline, procaterol and 
SNC 80 ((+)-4-[(aR)-a-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3 
methoxybenzyl]-N,N-diethylbenzamide) were all obtained from Tocris Biosciences. 
All cell culture agents, unless stated, were obtained from Cambrex.  Glucose-free 
DMEM was obtained from Invitrogen, and FBS (foetal bovine serum) was obtained 
from BioSera. 
[
3
H]-adenine was obtained from Amersham Biosciences; [3H]-myo-inositol was 
obtained from M.P Biomedicals. 
Antibodies were obtained from the following suppliers: monoclonal BKCa channel  
subunit from Beckon-Dickinson; polyclonal BKCa channel β4 subunit and 
monoclonal phospho-specific ERK1/2 (Thr
202
/Tyr
204
) from Sigma-Aldrich; 
polyclonal phospho-specific PKB (Ser
473
), monoclonal total unphosphorylated 
ERK1/2 and polyclonal total unphosphorylated PKB from New England Biolabs 
(U.K.) Ltd; and monoclonal cytochrome c from Santa Cruz Biotechnology. All other 
chemicals were of analytical grade. 
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3. Functional GPCR studies 
3.1.  Functional expression of adenosine receptors on H9c2 cells 
Adenosine is released from myocardial tissue during ischaemia or 
ischaemia/reperfusion (I/R), exerting cardioprotective effects against ischaemic 
injury/damage caused by reperfusion (Mubagwa & Flameng 2001; Fryer et al, 2002).  
Cardiomyocytes have been shown to express the adenosine A1, A2A and A3 receptor 
subtypes (Germack & Dickenson, 2004; for review see Peart & Headrick, 2007), but 
the presence of functional adenosine receptors on H9c2 cells has not been reported.  
In this study GPCR expression on H9c2 cells has been investigated by measuring the 
effects of selective receptor agonists and antagonists on [
3
H]-cAMP accumulation. 
CPA, the selective A1 receptor agonist, gave a modest inhibition of forskolin-induced 
cAMP accumulation (maximum inhibition occurring at 100 nM; 22.0 ± 4.2%; n=6; 
see Fig.3.1) but at higher concentrations produced a significant augmentation of 
cAMP-accumulation (maximum effect at 10 μM, 288 ± 56%, n=5, p<0.01).  CGS 
21680, the  adenosine A2A receptor agonist, did not increase cAMP accumulation 
(see Fig.3.2).  CI-IB-MECA, the Gi-coupled A3 receptor agonist (up to 1 μM), had no 
effect on forskolin-stimulated cAMP accumulation.  However, 10 μM Cl-IB-MECA 
induced a significant increase in cAMP accumulation (179.6  15% compared to 
forskolin response alone = 100%, n=5, p<0.05, see Fig.3.3).   
The inhibition afforded by CPA was reversed by pertussis toxin (PTX), a specific 
blocker of Gi protein (119.1 ± 4% of forskolin response in the presence of PTX; n=6; 
see Fig.3.4), and by the adenosine A1 receptor antagonist DPCPX (107.4 ± 7% of 
forskolin response in the presence of DPCPX; n=4; see Fig.3.4).   
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The augmentation of cAMP accumulation induced by CI-IB-MECA was blocked by 
the adenosine A1 receptor antagonist DPCPX (112.2  7% of forskolin response in 
the presence of DPCPX; n=4; see Fig.3.5) but not significantly by the adenosine A3 
receptor antagonist MRS 1220 (130.8 ± 11% of forskolin response in the presence of 
MRS 1220; n=4; see Fig.3.5). 
These data suggest that H9c2 cells functionally express Gi-coupled adenosine A1 
receptors, but not adenosine A2A or A3 receptors, and that at high agonist 
concentrations the adenosine A1 receptor can also couple to Gs protein. 
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Figure 3.1: CPA-mediated effects on forskolin-induced cAMP accumulation in H9c2 cells.  
Cells were pre-treated with the indicated concentrations of the selective adenosine A1 receptor 
agonist CPA for 5 minutes prior to the addition of 10 μM forskolin for a further 10 minutes.  
Data expressed as the percentage of forskolin response (=100%).  Each point represents mean ± 
S.E.M. of 5 separate experiments each performed in triplicate.  (b) is an enlargement of the frame 
in (a).  * p<0.05 vs. forskolin alone response; ** p<0.01 vs. forskolin alone response. 
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Figure 3.2: CGS 21680-mediated cAMP accumulation in H9c2 cells. Cells were treated 
with the indicated concentrations of the selective adenosine A2A receptor agonist CGS 21680 
hydrochloride for 15 minutes.  Data expressed as percentage of basal cAMP accumulation 
(=100%).  Each point represents mean ± S.E.M of 6 separate experiments each performed in 
triplicate.  
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Figure 3.3: CI-IB-MECA-mediated effects on forskolin-induced cAMP accumulation 
in H9c2 cells.  Cells were pre-treated with the indicated concentrations of the adenosine A3 
receptor agonist CI-IB-MECA for 5 minutes prior to the addition of 10 μM forskolin for a 
further 10 minutes.  Data expressed as the percentage of forskolin response (=100%).  Each 
point represents mean ± S.E.M. of 5 separate experiments each performed in triplicate.  * 
p<0.05 vs. forskolin alone response. 
64 
 
(a)
Controls PTX 
40
60
80
100
120
Forskolin
CPA
*
*
*
c
A
M
P
 a
c
c
u
m
u
la
ti
o
n
(%
 o
f 
F
o
rs
k
o
li
n
 r
e
s
p
o
n
s
e
)
 
(b)
Controls DPCPX
40
60
80
100
120
Forskolin
CPA
*
c
A
M
P
 a
c
c
u
m
u
la
ti
o
n
(%
 o
f 
F
o
rs
k
o
li
n
 r
e
s
p
o
n
s
e
)
 
Figure 3.4: The effect of pertussis toxin (PTX) and DPCPX on CPA-induced inhibition 
of forskolin-mediated cAMP accumulation in H9c2 cells.  (a) Control and PTX-treated 
cells (100 ng/ml; 16 hours) were pre-treated with 100 nM CPA for 5 minutes prior to the 
addition of 10 μM forskolin for a further 10 minutes.  (b) Control and DPCPX-treated cells 
(10 μM) were pre-treated with 100 nM CPA for 5 minutes prior to the addition of 10 μM 
forskolin for a further 10 minutes.  Data expressed as the percentage of forskolin control 
response (=100%).  Each point represents mean ± S.E.M. of 4 separate experiments each 
performed in triplicate.  * p<0.05 vs. forskolin alone response. 
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Figure 3.5: The effect of MRS 1220 and DPCPX on CI-IB-MECA-induced 
augmentation of forskolin-mediated cAMP accumulation.  (a) Control and MRS 1220-
treated cells (10 μM) were pre-treated with 10 μM CI-IB-MECA for 5 minutes prior to the 
addition of 10 μM forskolin for a further 10 minutes.  (b) Control and DPCPX-treated cells 
(10 μM) were pre-treated with 10 μM CI-IB-MECA for 5 minutes prior to the addition of 10 
μM forskolin for a further 10 minutes.  Data expressed as the percentage of forskolin control 
response (=100%).  Each point represents mean ± S.E.M. of 4 separate experiments each 
performed in triplicate.  *** p<0.001 vs. forskolin alone response. 
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3.2.  Functional expression of opioid receptors on H9c2 cells 
It has been shown that during periods of stress (e.g. cardiac ischaemia) the synthesis 
and release of some opioid peptides are increased, leading to modulation of response 
and cytoprotection (Clement-Jones et al 1980; Falcone et al 1993).  The receptors are 
widely distributed throughout the central nervous system and periphery; it has been 
reported that the κ- and δ-opioid receptors are the dominant subtypes present in rat 
heart (Zimlichman et al, 1996), and there is supporting data for the involvement of 
both receptors in cardioprotection (Valtchanova-Matchouganska & Ojewole, 2003).  
The presence of functional κ- and δ-opioid receptors on H9c2 cells has not been 
reported, so this study investigated this by measuring the effects of selective receptor 
agonists and antagonists on [
3
H] - cAMP accumulation.  
The δ-opioid receptor agonist SNC 80 had no effect on forskolin-induced cAMP 
accumulation (see Fig.3.6), whereas the κ-opioid agonist (-)-U-50488 induced a 
robust inhibition (maximal inhibition occurring at 1 μM, 25.5 ± 7.4%, n=4, p<0.05, 
see Fig.3.7).  The Gi-protein blocker PTX attenuated (-)-U-50488-mediated 
inhibition of cAMP accumulation (15 ± 2.6% reduction of forskolin response in the 
presence of PTX compared to 27.5 ± 4.1% reduction of forskolin response seen in 
controls, n=4, see Fig.3.8a) and the selective kappa-opioid receptor antagonist nor-
Binaltorphimine completely reversed (-)-U-50488-mediated inhibition of cAMP 
accumulation (112.4 ± 11.4% of forskolin response in the presence of nor-BIN,  n=4, 
see Fig.3.8b).  
Overall, these data suggest that H9c2 cells functionally express Gi-coupled κ-opioid 
receptors, but not δ-opioid receptors. 
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Figure 3.6: SNC 80-mediated effect on forskolin-induced cAMP accumulation in H9c2 
cells.  Cells were pre-treated with the indicated concentrations of the selective δ-opioid 
receptor agonist SNC 80 for 5 minutes prior to the addition of 10 μM forskolin for a further 
10 minutes.  Data expressed as the percentage of forskolin response (=100%).  Each point 
represents mean ± S.E.M. of 4-6 separate experiments each performed in triplicate.  
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Figure 3.7: (-)-U-50488-mediated effect on forskolin-induced cAMP accumulation in 
H9c2 cells.  Cells were pre-treated with the stated concentrations of the selective κ-opioid 
receptors agonist for 5 minutes prior to the addition of 10 μM forskolin for a further 10 
minutes.  Data expressed as the percentage of forskolin response (=100%).  Each point 
represents mean ± S.E.M of 5 separate experiments each performed in triplicate.  * p<0.05 
vs. forskolin alone response. 
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Figure 3.8: The effects of PTX and nor-BIN on (-)-U-50488-mediated inhibition of 
forskolin-induced cAMP accumulation in H9c2 cells.  (a) Control and PTX-treated cells 
(100 ng/ml; 16 hours) were pre-treated with 1 μM (-)-U-50488 for 5 minutes prior to the 
addition of 10 μM forskolin for a further 10 minutes.  (b) Control and nor-BIN-treated cells 
(10 μM) were pre-treated with 1 μM (-)-U-50488 for 5 minutes prior to the addition of 10 
μM forskolin for a further 10 minutes.  Data expressed as the percentage of forskolin control 
response (=100%).  Each point represents mean ± S.E.M. of 5 separate experiments each 
performed in triplicate.  * p<0.05 vs. forskolin alone response. 
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3.3.  Functional expression of beta-adrenergic receptors on H9c2 cells 
During ischaemia it is well accepted that catecholamines, such as noradrenaline, are 
released and consequential activation of G protein-coupled adrenergic receptors 
occurs.  The presence of both the β1 and β2 subtypes has been demonstrated on H9c2 
cells using radioligand binding studies (Dangel et al, 1996) and using antibody 
imaging (Ianoul et al, 2005).  In this study, the presence of functional beta-
adrenergic receptors on H9c2 cells was investigated by measuring the effects of 
selective receptor agonists and on [
3
H]-cAMP accumulation. 
The non-selective β-adrenergic receptor agonist isoprenaline stimulated a 
concentration-dependent increase in cAMP accumulation (maximal effect occurring 
at 100 nM; 622 ± 117% basal response; n = 4; see Fig.3.9).  The selective β1 agonist 
dobutamine stimulated cAMP accumulation to an extent (10 μM induced 174 ± 57% 
basal response; n=4; see Fig.3.10), however, a larger response was seen from the 
selective β2 agonist procaterol (1 μM induced 203 ± 29% basal response, n=4; 10 μM 
induced 598 ± 150% basal response; n=4; see Fig.3.11). 
These data suggest that the Gs-coupled β2 adrenergic receptor could be present on 
H9c2 cells, but the presence of a functional β1 adrenergic receptor is less clear. 
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Figure 3.9: The effect of isoprenaline on cAMP accumulation in H9c2 cells.  Cells were 
treated with the indicated concentrations of isoprenaline for 10 minutes.  Data expressed as 
the percentage of basal response (=100%).  Each point represents mean ± S.E.M of 4 
separate experiments each performed in triplicate.  * p<0.05 vs. basal response, ** p<0.01 
vs. basal response. 
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Figure 3.10: The effect of dobutamine on cAMP accumulation in H9c2 cells.  Cells were 
treated with the indicated concentrations of the β1 receptor agonist dobutamine for 10 
minutes.  Data expressed as the percentage of basal response (=100%).  Each point 
represents mean ± S.E.M of 4 separate experiments each performed in triplicate. 
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Figure 3.11: The effect of procaterol on cAMP accumulation in H9c2 cells.  Cells were 
treated with the indicated concentrations of the β2 receptor agonist procaterol for 10 minutes.  
Data expressed as the percentage of basal response (=100%).  Each point represents mean ± 
S.E.M of 4 separate experiments each performed in triplicate.  * p<0.05 vs. basal response. 
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3.4:  Functional expression of other Gi and Gq protein-coupled 
receptors on H9c2 cells 
 
The presence of a selection of other GPCRs on H9c2 cells was also investigated as, 
to date, an extensive functional study has not been reported.   
Firstly, the effects of baclofen and acetylcholine on forskolin-induced cAMP 
accumulation were tested.  Baclofen is an agonist at the Gi-coupled GABAB receptor, 
which has been found to be expressed in mammalian heart and exert a 
cardioprotective effect during ischaemia (Lorente et al, 2000).  In H9c2 cells this 
agent provided some inhibition of cAMP accumulation, but not to a statistically 
significant level (maximal inhibition occurring at 10 nM, 83 ± 9% of forskolin 
response = 100%, n=4, p>0.05, see fig.3.12a).  Therefore, functional expression of 
this receptor on H9c2 cells is debatable.   
There are several subtypes of acetylcholine receptor, and the Gi-coupled muscarinic 
M2 subtype is known to have parasympathetic effects in the heart. However, no 
significant effect on cAMP accumulation was observed from acetylcholine 
suggesting that the muscarinic M2 receptor is not functionally expressed on H9c2 
cells (see fig.3.12). 
It was also decided to test a range of agonists at Gq-coupled receptors by measuring 
the accumulation of radiolabelled inositol trisphosphate (IP3) following receptor 
stimulation.  As previously mentioned, mammalian cardiomyocytes express Gi-
coupled M2 receptors, but there is also evidence supporting the expression of Gq-
coupled M1 receptors (Sharma et al, 1997).  Acetylcholine did stimulate an increase 
in IP3 accumulation in H9c2 cells, but not significantly implying that the Gq-coupled 
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muscarinic receptors may not be functionally expressed (100 µM, 132 ± 12% of 
control = 100%, n=6, p>0.05, see fig.3.13).   
Histamine H1 receptors predominantly couple to Gq protein, but there is evidence 
stating that the H2 receptor can also bind Gq protein (Kühn et al, 1996).  Both of 
these subtypes have been found to have a role in the mediation of the effects of 
histamine in the heart (Flynn et al, 1979), but this study found no evidence for 
functional expression of a histamine receptor on H9c2 cells (100 µM, 94 ± 8% of 
control = 100%, n=6, p>0.05, see fig. 3.13). 
As mentioned previously, catecholamines such as noradrenaline are released from 
cardiac tissue during ischaemia; it has been found that Gq-coupled  α1A, α1B and α1D-
adrenergic receptors are all expressed in rat heart, with the α1B receptor being the 
predominant subtype and mainly responsible for the cardioprotective effects of α-
adrenergic receptor agonism (Gao et al, 2007).  Treatment of H9c2 cells with 
noradrenaline did result in a sizeable increase in IP3 accumulation – but this was not 
statistically significant (100 µM, 150 ± 15% of control = 100%, n=4, p>0.05, see fig. 
3.13).   
Cardiac ischaemia stimulates the release of ATP and UTP, which then activate 
purinergic P2Y receptors.  The expression of P2Y4 receptors, which preferentially 
bind UTP, is low in the heart but the expression of P2Y2 (equal affinity for ATP and 
UTP) and P2Y11 (preferentially bind ATP) is high (Erlinge & Burnstock, 2008).  
Although ATP did not elicit an increase in IP3 accumulation in H9c2 cells (100 µM, 
103 ± 15% of control = 100%, n=6, p>0.05, see fig.3.13), UTP gave a sizeable 
response (100 µM, 199 ± 15% of control = 100%, n=4, p<0.01, see fig.3.13).  This 
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suggests that one or more of the UTP-binding receptors are functionally expressed on 
H9c2 cells. 
In conclusion, these data provide evidence for the functional expression of Gi-
coupled adenosine A1 and κ-opioid receptors, Gs-coupled β2 adrenergic receptors and 
Gq-coupled UTP-binding P2Y purinergic receptors on H9c2 cells.   
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Figure 3.12: The effects of baclofen and acetylcholine of forskolin-induced cAMP 
accumulation in H9c2 cells.  Cells were pre-treated with the indicated concentrations of (a) 
the GABAB receptor agonist baclofen or (b) the muscarinic receptor agonist ACh for 5 
minutes prior to the addition of 10 μM forskolin for a further 10 minutes.  Data expressed as 
the percentage of forskolin response (=100%).  Each point represents mean ± S.E.M. of 4 
separate experiments each performed in triplicate.   
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Figure 3.13: The effects of selected agonists on inositol phosphate accumulation in H9c2 
cells.  Cells were incubated with the selected agonists (noradrenaline (NA), ATP, UTP, 
histamine (HA), ACh all at 100 μM) for 30 minutes.  Data expressed as the percentage of 
basal response (=100%).  Each point represents mean ± S.E.M. of 4 separate experiments 
each performed in triplicate.   
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4.  Cardioprotective potential of functionally expressed 
receptors on H9c2 cells 
 
4.1.  Determining the effects of GPCR agonists against hypoxia-
induced cell death in H9c2 cells 
 
As mentioned in the previous chapter, all of the GPCRs found to be functionally 
expressed on H9c2 cells have been implicated in cardioprotective mechanisms so it 
was important to assess such properties in this cell line.  Initially it was necessary to 
investigate the effect of hypoxia upon H9c2 cells, allowing the ideal length of time in 
hypoxia to be chosen for further experiments involving pharmacological 
preconditioning.       
Cell death was measured following 1, 2, 4, 6, 8 and 24 hours in hypoxia (0.5% O2) 
using assays to measure MTT reduction, LDH release and caspase-3 activity (see 
fig.4.1).  6 hours of hypoxia was chosen for further experiments as it produced a 
large response in all of the assays (MTT reduction was decreased to 33 ± 8% of 
control, n=4, p<0.01; LDH release was increased to 352 ± 101% of control, n=4; 
caspase-3 activity was increased to 235 ± 19% of control, n=4, p<0.05) and allowed 
a whole experiment with preconditioning and viability assay to be completed in a 
working day. 
The adenosine A1 receptor agonist CPA (100 nM) was the only drug to increase 
MTT reduction during hypoxia (123 ± 24% compared to 65 ± 13% = hypoxic 
control, n=4, p<0.05, see fig.4.2a).  Interestingly, the β2 adrenergic receptor agonist 
procaterol (10 µM) significantly increased MTT reduction during normoxia (164 ± 
34% compared to normoxic control = 100%, n=4, p<0.01). 
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LDH release during hypoxia was significantly reduced by CPA (100 nM, 102 ± 10% 
compared to 161 ± 10% = hypoxic control, n=7, p<0.01, see fig.4.2b) and the κ-
opioid receptor agonist (-)-U-50488 (100 nM, 112 ± 9% compared to 161 ± 10% = 
hypoxic control, n=7, p<0.05).  None of the drugs had a significant effect during 
normoxia. 
CPA also significantly reduced hypoxia-induced caspase-3 activity (100 nM, 103 ± 
14% compared to 174 ± 11% = hypoxic control, n=5, p<0.05, see fig.4.2c), as did the 
non-selective beta-adrenergic receptor agonist isoprenaline (10 µM, 99 ± 15% 
compared to 174 ± 11% = hypoxic control, n=5, p<0.05).  As before, none of the 
drugs had a significant effect during normoxia. 
Overall, the most promising target for protection against hypoxia-induced cell death 
in H9c2 cells was the adenosine A1 receptor, which attenuated cell death according 
to all three parameters measured.  Stimulation of the beta-adrenergic receptors also 
appeared to be beneficial, as did activation of the κ-opioid receptor.  Importantly, 
these data show that i) it is possible to stimulate a preconditioning response in H9c2 
cells, and ii) the protective properties of activation of the adenosine A1 receptor 
observed in cardiac myocytes (Safran et al, 2001) can be reproduced in H9c2 cells.  
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Figure 4.1: Effect of hypoxia on H9c2 cell viability over time.  Cells were exposed to 
hypoxia for the stated times then cell viability was assessed via (a) MTT reduction, (b) LDH 
release and (c) caspase-3 activity.  Data expressed as the percentage of control response 
(=100%).  Each point represents mean ± S.E.M. of 4-6 separate experiments; for each 
experiment the mean was taken from 2 (caspase-3) or 6 (MTT and LDH) replicates.                       
* p<0.05 vs. control; ** p<0.01 vs. control; *** p<0.001 vs. control. 
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Figure 4.2: Effects of GPCR agonists on hypoxia-induced cell death in H9c2 cells.  Cells 
were exposed the stated agonist (Concentrations as follows: 10 μM isoprenaline, 10 μM 
dobutamine, 10 μM procaterol, 100 nM CPA, 100 nM (-)-U-50488) for 30 minutes prior to 6 
hours hypoxia.  Cell viability was measured by (a) MTT reduction, (b) LDH release and (c) 
caspase-3 activity.  Data expressed as the percentage of Normoxic control response 
(=100%).  Each point represents mean ± S.E.M. of 4-6 separate experiments; for each 
experiment the mean was taken from 2 (caspase-3) or 6 (MTT and LDH) replicates.  ## 
p<0.01 vs. normoxic control; * p<0.05 vs. hypoxic control; ** p<0.01 vs. hypoxic control. 
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4.2:  Establishing a role for the ATP-sensitive potassium channel 
(KATP) and the large-conductance calcium-activated potassium 
channel (BKCa channel)  
 
KATP channels have a widely accepted role in cardioprotection and ischaemic 
preconditioning (for review see Gross & Peart, 2003).  Sarcolemmal KATP 
(sarcoKATP) channels were the first to be described, with evidence for a 
mitochondrial KATP (mitoKATP) emerging at a later date.  Garlid et al (1997) were the 
first to publish data showing a link between the mitoKATP channel and 
cardioprotection using diazoxide and rat hearts; therefore this study postulated that  
diazoxide would have a protective effect against hypoxia in the cardiac H9c2 cell 
line.   
Diazoxide significantly reduced hypoxia-induced LDH release (123 ± 3% compared 
to 156 ± 9% = hypoxic control, n=5, p<0.01, see fig.4.3), and this effect was reversed 
by co-treatment with the KATP channel blocker 5-HD (153 ± 6% compared to 156 ± 
9% = hypoxic control, n=5, see fig.4.3).  This data supports the presence of a KATP 
channel in H9c2 cells, and as diazoxide is a potent opener of cardiac mitoKATP 
channels but a weak sarcoKATP opener it is highly likely that the channel in question 
is located to the mitochondria .  However, as much evidence already exists regarding 
the role of the KATP channel in cardioprotection and its link with GPCRs, for the 
remainder of this study  it was decided to proceed purely with research in to the 
Ca
2+
-activated K
+
 channel.    
Siemen et al (1999) first described the presence of a Ca
2+
-activated K
+
 channel on the 
inner mitochondrial membrane of human glioma LN229 cells, and since this 
discovery the activation of mitoBKCa channels has been implicated in 
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cardioprotection against ischemia and reperfusion injury in various models including 
isolated perfused guinea pig hearts (Xu et al, 2002), anesthetised dogs (Shintani et al, 
2004) and isolated guinea pig ventricular myocytes (Sato et al, 2005).  It was, 
therefore, postulated that activation of these channels would also elicit a protective 
effect against hypoxia-induced cell death in H9c2 cells.   
The BKCa channel activator, NS1619 (10 µM), significantly decreased LDH release 
during hypoxia (111 ± 10% compared to 161 ± 12% = hypoxic control, n=7, p<0.05, 
see fig.4.4) and this was attenuated by the selective BKCa channel blockers paxilline 
(1 µM, 151 ± 15% compared to 161 ± 12% = hypoxic control, n=7) and iberiotoxin 
(10 nM, 141 ± 13% compared to 161 ± 12% = hypoxic control, n=5).  NS1619 (10 
µM) also considerably reduced caspase-3 activity during hypoxia (126 ± 11% 
compared to 195 ± 16% = hypoxia control, n=5, p<0.05, see fig.4.5), and this was 
completely reversed by both paxilline (207 ± 26% compared to 195 ± 16% = hypoxia 
control, n=5) and iberiotoxin (196 ± 59% compared to 195 ± 16% = hypoxia control, 
n=5). 
To confirm that the channel in question was the mitochondrial BKCa channel, 
mitochondria from H9c2 cells were collected and probed with antibodies for the 
BKCa-α and β4 subunits and the mitochondrial marker cytochrome c (see fig.4.6).  
Bands for the BKCa-α and β4 subunits were clearly observed in the mitochondrial 
fraction, but not in the cytoplasmic fraction or total extract.  Cytochrome c was 
abundant in the mitochondrial fraction but absent from the cytoplasmic fraction, 
confirming the purity of the fractions. 
In conclusion, these data show that NS1619 is activating the mitochondrial BKCa 
channel, and that this channel has cytoprotective potential in H9c2 cells. 
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Figure 4.3: Establishing a role for the KATP channel in protection against hypoxia-
induced cell death in H9c2 cells.  Cells were exposed to the channel blocker 5-HD (100 
μM) for 45 minutes, with the addition of diazoxide (30 μM) for the final 30 minutes, prior to 
6 hours hypoxia.  Cell viability was assessed via LDH release.  Data expressed as the 
percentage of normoxic control response (=100%).  Each point represents mean ± S.E.M. of 
5 separate experiments; for each experiment the mean was taken from 6 replicates.     ** 
p<0.01 vs. normoxic control. 
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Figure 4.4: Establishing a role for the BKCa channel in protection against hypoxia-
induced LDH release in H9c2 cells.  Cells were exposed to the channel blockers paxilline 
(1 μM) or iberiotoxin (10 nM) for 45 minutes, with the addition of NS1619 (10 μM) for the 
final 30 minutes, prior to 6 hours hypoxia.  Cell viability was assessed via LDH release.  
Data expressed as the percentage of normoxic control response (=100%).  Each point 
represents mean ± S.E.M. of 5-7 separate experiments; for each experiment the mean was 
taken from 6 replicates.  * p<0.05 vs. normoxic control.  
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Figure 4.5: Establishing a role for the BKCa channel in protection against hypoxia-
induced caspase-3 activation in H9c2 cells.  Cells were exposed to the channel blockers 
paxilline (1 μM) or iberiotoxin (10 nM) for 45 minutes, with the addition of NS1619 (10 
μM) for the final 30 minutes, prior to 6 hours hypoxia.  Cell viability was assessed via 
caspase-3 activity.  Data expressed as the percentage of normoxic control response (=100%).  
Each point represents mean ± S.E.M. of 5-7 separate experiments; for each experiment the 
mean was taken from 2 replicates.  * p<0.05 vs. normoxic control. 
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Figure 4.6: Establishing the presence of the mitochondrial BKCa channel subunits in 
H9c2 cells.  Mitochondria were extracted from H9c2 cells by differential centrifugation and 
probed with antibodies specific to the BKCa-α and BKCa-β4 subunits (30 μg protein was 
loaded per lane).  Cyto represents the cytoplasmic fraction; TE represents total extract.  
Cytochrome c was used to confirm purity of the mitochondrial fraction.  Blots are 
representative of 4 separate experiments. 
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4.3:  Determining a link between the adenosine A1 receptor and the 
BKCa channel  
 
There is some evidence that BKCa channels have a role in cardioprotection induced 
by some GPCR agonists including the κ-opioid receptor agonist (-)-U-50488 (Cao et 
al, 2005).  However, to date, the role of the BKCa channel in adenosine receptor-
induced cardioprotection has yet to be investigated.  The adenosine A1 receptor 
activates similar Gi protein-modulated pathways to the κ-opioid receptor, so it was 
hypothesized that the BKCa channel may also feature in cardioprotection induced by 
this receptor. 
As before, activation of the adenosine A1 receptor with CPA reduced LDH release 
during hypoxia (100 nM, 135 ± 10% compared to 191 ± 8% = hypoxic control, n=6, 
p<0.05, see fig.4.7a).  This effect was attenuated by the A1 receptor antagonist 
DPCPX (10 µM, 171 ± 5% compared to 191 ± 8% = hypoxic control, n=6), and 
interestingly, also by the BKCa channel blockers paxilline (1 µM, 177 ± 9% 
compared to 191 ± 8% = hypoxic control, n=6) and iberiotoxin (10 nM, 173 ± 7% 
compared to 191 ± 8% = hypoxic control, n=6). 
This was also the case when assessing caspase-3 activity.  CPA reduced caspase-3 
activity during hypoxia (128 ± 12% compared to 184 ± 16% = hypoxic control, n=5, 
p<0.05, see fig.4.7b), and this was prevented by both paxilline (174 ± 17% compared 
to 184 ± 16% = hypoxic control, n=5) and iberiotoxin (181 ± 30% compared to 184 ± 
16% = hypoxic control, n=5). 
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None of the blockers affected LDH release or caspase-3 activity when used alone 
(data not shown).  These data have, for the first time, uncovered a role for the BKCa 
channel in adenosine A1 receptor-induced protection against hypoxia. 
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Figure 4.7: The effect of BKCa channel blockers on CPA-mediated protection against 
hypoxia-induced cell death in H9c2 cells.  Cells were exposed to paxilline (1 μM) or 
iberiotoxin (10 nM) for 45 minutes, with the addition of CPA (100 nM) for the final 30 
minutes prior to 6 hours hypoxia.  Cell viability was assessed via (a) LDH release or (b) 
caspase-3 activity.  Data expressed as the percentage of normoxic control response (=100%).  
Each point represents mean ± S.E.M. of 5-6 separate experiments; for each experiment the 
mean was taken from 2 (caspase-3) or 6 (LDH) replicates.  * p<0.05 vs. hypoxic control.  
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5. The role of protein kinases ERK1/2 and PKB in 
adenosine A1 receptor and BKCa channel-mediated 
cytoprotection 
 
Several protein kinases have been implicated in ischaemic pre- and postconditioning, 
including ERK1/2 and PKB. Both of these are pro-survival kinases included in the 
RISK pathway (Reperfusion Injury Salvage Kinase), and have been associated with 
the cardioprotective effects of KATP channels (de Toit et al, 2008; Grossini et al, 
2009; for extensive review see Hausenloy & Yellon, 2007).  In addition, there is 
existing data stating that PKB can be activated by the BKCa channel opener NS1619 
(100 µM) in neurones (Gáspár et al, 2008).  Both kinases have been documented to 
form part of the cardioprotective signalling cascades initiated by activation of 
adenosine receptors (Germack et al, 2004; Downey et al, 2008), so when taking this 
knowledge into account it was postulated that ERK1/2 and PKB are involved in 
signal transduction mediated by the adenosine A1 receptor and BKCa channel. 
However, in this study it was found that 10 µM NS1619 did not induce 
phosphorylation of ERK1/2 (see fig.5.1) or PKB (see fig.5.2) in H9c2 cells; 
conversely, 100 µM significantly inhibited the activation of both protein kinases.  
ERK1/2 was maximally inhibited following 15 minutes treatment (39 ± 9% of 
control; n=5; p<0.05; see fig.5.3), after which levels increased over time and 
phosphorylation was actually raised above control following 180 minutes treatment 
(144 ± 25% of control; n=5; p>0.05).  Maximum inhibition of PKB phosphorylation 
occurred following 60 minutes treatment with 100 µM NS1619 (32 ± 15% of 
control; n=4; p<0.05; see fig.5.4), after which the level of activation gradually 
increased but did not reach that of the control.   
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It was postulated that NS1619 may activate ERK1/2 and PKB during periods of 
stress, such as hypoxia.  However, when H9c2 cells were pre-treated with NS1619 
(10 µM) then subjected to hypoxia for 1, 2, 4, or 6 hours no phosphorylation of either 
protein was observed (see figs.5.5 and 5.6). 
It has previously been shown that CPA can activate ERK1/2 and PKB in both 
cardiomyocyes and the DDT(1)MF-2 hamster vas deferens smooth muscle cell line 
(Germack & Dickenson, 2000; Germack et al, 2004).  In this study it was also found 
that CPA activated ERK1/2 in H9c2 cells in a transient manner, with maximal 
phosphorylation occurring with 5 minutes treatment (264 ± 26% of control; n=4; 
p<0.001; see fig.5.7).  However, activation of PKB was not observed (see fig.5.8). 
Earlier results have shown that by blocking the BKCa channel CPA-mediated 
protection against hypoxia-induced cell death in H9c2 cells can be attenuated.  It was 
decided to investigate whether ERK1/2 or PKB are involved in this process as it has 
been shown that ERK1/2 is phosphorylated following activation of the adenosine A1 
receptor, and is well documented that both ERK1/2 and PKB are implicated in 
cytoprotective pathways.  However, in this model CPA (100 nM)-induced ERK1/2 
phosphorylation was not blocked by paxilline (1 µM; 277 ± 75% of control 
compared to 227 ± 48% of control for CPA alone; n=4; see fig.5.9) or iberiotoxin (10 
nM; 223 ± 26%  of control compared to 227 ± 48% of control for CPA alone; n=4; 
see fig.5.9).  No phosphorylation of PKB was observed (see fig.5.10). 
From these data it appears that ERK1/2 and PKB are not activated upstream of BKCa 
channel-mediated signal transduction since no phosphorylation of either protein 
kinase was detected.  It is important to note, however, that compartmentalisation of 
these activated proteins has been described (Chuderland et al, 2008; Gonzalez & 
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McGraw, 2009).  It is therefore possible that if this is the case in H9c2 cells, by using 
whole cell lysates the phosphorylated proteins may have been diluted to a level 
undetectable by the method used.   
The sizeable phosphorylation of ERK1/2 by stimulation of the adenosine A1 receptor 
further confirms earlier data relating to the functional expression of this receptor on 
H9c2 cells – and although ERK1/2 does not seem to be activated upstream of 
adenosine A1 receptor/BKCa channel signalling it is possible that it is an intermediate 
step in this pathway. 
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Figure 5.1: The effect of 10 μM NS1619 on phosphorylation of ERK1/2 in H9c2 cells.  
Cells were exposed to NS1619 for the indicated periods of time then cell lysates were 
collected and probed for phosphorylated ERK1/2 and total ERK1/2.  (a) Representative blot 
with exposure time (in minutes) underneath.  (b) Data expressed as percentage of untreated 
controls.  Each bar represents mean ± S.E.M. of 6 separate experiments. 
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Figure 5.2: The effect of 10 μM NS1619 on phosphorylation of PKB in H9c2 cells.  Cells 
were exposed to NS1619 for the indicated periods of time then cell lysates were collected 
and probed for phosphorylated PKB (Ser 473) and total PKB.  (a) Representative blot with 
exposure time (in minutes) underneath.  (b) Data expressed as percentage of untreated 
controls.  Each bar represents mean ± S.E.M. of 6 separate experiments. 
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Figure 5.3: The effect of 100 μM NS1619 on phosphorylation of ERK1/2 in H9c2 cells.  
Cells were exposed to NS1619 for the indicated periods of time then cell lysates were 
collected and probed for phosphorylated ERK1/2 and total ERK1/2.  (a) Representative blot 
with exposure time (in minutes) underneath.  (b) Data expressed as percentage of untreated 
controls.  Each bar represents mean ± S.E.M. of 5 separate experiments. * p<0.05 vs. 
untreated pERK1/2 control. 
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Figure 5.4: The effect of 100 μM NS1619 on phosphorylation of PKB in H9c2 cells.  
Cells were exposed to NS1619 for the indicated periods of time then cell lysates were 
collected and probed for phosphorylated PKB (Ser 473) and total PKB.  (a) Representative 
blot with exposure time (in minutes) underneath.  (b) Data expressed as percentage of 
untreated controls.  Each bar represents mean ± S.E.M. of 4 separate experiments. *p<0.05 
vs. untreated pPKB control. 
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Figure 5.5: The effect of NS1619 on ERK1/2 phosphorylation during hypoxia.  H9c2 
cells were treated with 10 µM NS1619 (or serum-free DMEM for controls) for 30 minutes 
prior to hypoxic/normoxic incubation for the indicated amount of time (hours; see graph).  
Cell lysates were then collected and probed for phosphorylated ERK1/2 and total ERK1/2.  
(a) Representative blot for phosphorylated ERK1/2 (b) Representative blot for total ERK1/2 
(c) Data expressed as percentage of 1 hour untreated normoxic control, total ERK1/2 not 
shown.  Each bar represents mean ± S.E.M. of 6 separate experiments. 
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Figure 5.6: The effect of NS1619 on PKB phosphorylation during hypoxia.  H9c2 
cells were treated with 10 µM NS1619 (or serum-free DMEM for controls) for 30 minutes 
prior to hypoxic/normoxic incubation for the indicated amount of time (hours; see graph).  
Cell lysates were then collected and probed for phosphorylated PKB (Ser 473) and total 
PKB.  (a) Representative blot for phosphorylated PKB (b) Representative blot for total PKB 
(c) Data expressed as percentage of 1 hour untreated normoxic control, total PKB not shown.  
Each bar represents mean ± S.E.M. of 6 separate experiments. 
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Figure 5.7: CPA-induced phosphorylation of ERK1/2 in H9c2 cells.  Cells were treated 
with 100 nM CPA for the indicated amounts of time then cell lysates were collected and 
probed for phosphorylated ERK1/2 and total ERK1/2.  (a) Representative blot with exposure 
time (in minutes) underneath.  (b) Data expressed as percentage of untreated controls.  Each 
bar represents mean ± S.E.M. of 4 separate experiments.  *** p<0.001 vs. untreated 
pERK1/2 control. 
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Figure 5.8: The effect of CPA on PKB phosphorylation in H9c2 cells.  Cells were treated 
with 100 nM CPA for the indicated amounts of time then cell lysates were collected and 
probed for phosphorylated PKB and total PKB.  (a) Representative blot with exposure time 
(in minutes) underneath.  (b) Data expressed as percentage of untreated controls.  Each bar 
represents mean ± S.E.M. of 4 separate experiments.   
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Figure 5.9:  The effect of blocking the BKCa channel on CPA-induced ERK1/2 
phosphorylation in H9c2 cells.  Cells were exposed to paxilline (1 µM) or iberiotoxin (10 
nM) for 45 minutes, with the addition of CPA (100 nM) for the final 30 minutes.  Cell 
lysates were then collected and probed for phosphorylated ERK1/2 and total ERK1/2.  (a) 
Representative blot.  (b) Data expressed as percentage of untreated controls. Each bar 
represents mean ± S.E.M. of 4 separate experiments.  * p<0.05 vs. untreated pERK1/2 
control. 
108 
 
(a) 
    
Phosphorylated PKB
Total PKB
 
(b) 
C
on
tr
ol
C
PA P
ax
C
PA
 +
 P
ax
Ib
Tx
C
PA
 +
 Ib
Tx
0
50
100
150
pPKB
totPKB
P
K
B
(%
 c
o
n
tr
o
l)
 
Figure 5.10: The effect of blocking the BKCa channel on CPA-induced PKB 
phosphorylation in H9c2 cells.  Cells were exposed to paxilline (1 µM) or iberiotoxin (10 
nM) for 45 minutes, with the addition of CPA (100 nM) for the final 30 minutes.  Cell 
lysates were then collected and probed for phosphorylated PKB and total PKB.  (a) 
Representative blot.  (b) Data expressed as percentage of untreated controls. Each bar 
represents mean ± S.E.M. of 5 separate experiments.   
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6. The role of the BKCa channel in adenosine receptor-
mediated protection against hypoxia-reoxygenation 
 
6.1.  A model for hypoxia-reoxygenation in H9c2 cells 
Models using hypoxia-reoxygenation allow us to gain a more realistic insight into the 
damage caused by ischaemia/reperfusion and discovery of potential therapeutic 
agents.  This study utilised a model for hypoxia-reoxygenation in H9c2 cells 
consisting of 6 hours hypoxia as used for previous experiments, followed by 18 
hours of reoxygenation – a time point which had previously been used (Germack & 
Dickenson, 2005).  Preliminary data showed that this model was sufficient for 
initiating cell death in H9c2 cells as measured by LDH release (363 ± 70% compared 
to normoxic control = 100%, n=6, p<0.06, see fig.6.1a), but caspase-3 activity was 
not increased suggesting that apoptosis had not occurred (100.5 ± 11% compared to 
normoxic control = 100%, n=6, see fig.6.1b).   
For preconditioning, H9c2 cells were treated with pharmacological agents for 30 
minutes before the onset of the hypoxic incubation.  Activation of the adenosine A1 
receptor with CPA (100 nM) did not provide any protection against hypoxia-
reoxygenation induced cell death as measured by LDH release (100 ± 13% compared 
to untreated control = 100%, n=7, see fig.6.2).  Unexpectedly, treatment with the 
BKCa channel opener NS1619 (10 µM) raised LDH release (148 ± 8% of untreated 
control = 100%, n=11, p<0.01 vs. control, see fig.6.2).  This augmentation was 
reversed by co-treatment with paxilline (1 µM, 110 ± 6% of untreated control = 
100%, n=5, p<0.05 vs. NS1619 alone, see fig.6.3) and iberiotoxin (10 nM, 116 ± 7% 
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of untreated control = 100%, n=5, p<0.05 vs. NS1619 alone, see fig.6.3), confirming 
the involvement of the BKCa channel. 
To assess the postconditioning potential of pharmacological agents, treatment 
occurred after hypoxia at the start of reoxygenation.  Postconditioning is a more valid 
method for protection against myocardial infarction in a clinical setting as the 
stimulus is applied following a bout of ischaemia – with preconditioning it would be 
difficult to predict when treatment should occur.  NS1619- and CPA-mediated 
postconditioning both proved to be beneficial in the H9c2 model specified earlier 
(NS1619: 10 µM, 64 ± 4% of untreated control = 100%, n=7, p<0.001; CPA: 100 
nM, 59 ± 6% of untreated control = 100%, n=7, p<0.001, see fig. 6.4).  The 
protection afforded by NS1619 was reversed by paxilline (1 µM, 101 ± 11% of 
untreated control = 100%, n=5, p<0.05 vs. NS1619) and iberiotoxin (10 nM, 103 ± 
8% of untreated control = 100%, n=5, p<0.05 vs. NS1619, see fig. 6.5), confirming 
that it is mediated by the BKCa channel.   
CPA-mediated protection was reversed by the adenosine A1 receptor antagonist 
DPCPX (10 µM, 92 ± 7% of untreated control = 100%, n=6, p<0.01 vs. CPA, see 
fig. 6.6).  Interestingly, the BKCa channel blockers paxilline and iberiotoxin also 
significantly attenuated the CPA-mediated response suggesting a role for the BKCa 
channel in adenosine A1 receptor-mediated postconditioning in H9c2 cells (paxilline: 
1 µM, 83 ± 5% of untreated control = 100%, n=6, p<0.05 vs. CPA; iberiotoxin: 10 
nM, 84 ± 4% of untreated control = 100%, n=6, p<0.05 vs. CPA). 
 
 
111 
 
(a) 
Control HX HX/Reox
0
100
200
300
400
500
**
L
D
H
 r
e
le
a
s
e
(%
 c
o
n
tr
o
l)
 
(b) 
Control HX HX/Reox
0
50
100
150
200
**
C
a
s
p
a
s
e
-3
 a
c
ti
v
it
y
(%
 c
o
n
tr
o
l)
 
Figure 6.1: Cell death induced by hypoxia-reoxygenation in H9ce cells.  Cells were 
exposed to 6 hours normoxia (control), 6 hours hypoxia (HX) or 6 hours hypoxia followed 
by 18 hours reoxygenation (HX/Reox) then cell death was assessed by (a) LDH release or 
(b) caspase-3 activity.  Data expressed as percentage of control.  Each bar represents mean ± 
S.E.M from 6 separate experiments; for each experiment the mean was taken from 2 
(caspase-3) or 6 (LDH) replicates.  ** p<0.01 vs. control.   
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Figure 6.2: Preliminary data investigating the potential cardioprotective effects of 
preconditioning with CPA and NS1619.  H9c2 cells were exposed to NS1619 (10 µM) or 
CPA (100 nM) for 30 minutes prior to 6 hours of hypoxa followed by 18 hours of 
reoxygenation.  Data expressed as percentage of untreated controls exposed to 
hypoxia/reoxygenation (HX/Reox = 100%).  Each bar represents mean ± S.E.M. of 7-11 
separate experiments, for each experiment the mean was taken from 6 replicates.  ** p<0.01 
vs. HX/Reox. 
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Figure 6.3: The role of the BKCa channel in NS1619-mediated preconditioning in H9c2 
cells.  Cells were treated with paxilline (Pax, 1 µM) or iberiotoxin (IbTx, 10 nM) for 45 
minutes, with the addition of NS1619 (10 µM) for the final 30 minutes.  This preceded 6 
hours hypoxia followed by 18 hours reoxygenation. Data expressed as percentage of 
untreated controls exposed to hypoxia/reoxygenation (HX/Reox = 100%).  Each bar 
represents mean ± S.E.M. of 5-11 separate experiments, for each experiment the mean was 
taken from 6 replicates.  ** p<0.01 vs. HX/Reox; # p<0.05 vs. NS1619. 
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Figure 6.4: Preliminary data investigating the potential cardioprotective effects of 
postconditioning with CPA and NS1619.  H9c2 cells were exposed to 6 hours of hypoxia 
followed by 18 hours of reoxygenation.  For the first 30 minutes of reoxygenation, cells were 
exposed to NS1619 (10 µM) or CPA (100 nM) which was then removed for the remainder of 
reoxygenation.  Data expressed as percentage of untreated controls exposed to 
hypoxia/reoxygenation (HX/Reox = 100%).  Each bar represents mean ± S.E.M. of 7 
separate experiments, for each experiment the mean was taken from 6 replicates.  *** 
p<0.001 vs. HX/Reox. 
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Figure 6.5: The role of the BKCa channel in NS1619-mediated postconditioning in H9c2 
cells.  Cells were exposed to 6 hours of hypoxia followed by 18 hours of reoxygenation.  For 
the first 45 minutes of reoxygenation the cells were treated with paxilline (Pax, 1 µM) or 
iberiotoxin (IbTx, 10 nM) with the addition of NS1619 (NS, 10 µM) for the final 30 minutes 
of treatment.  Data expressed as percentage of untreated controls exposed to 
hypoxia/reoxygenation (HX/Reox = 100%).  Each bar represents mean ± S.E.M. of 5 
separate experiments, for each experiment the mean was taken from 6 replicates.  * p<0.05 
vs. HX/Reox; # p<0.05 vs. NS1619. 
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Figure 6.6: The role of the BKCa channel in CPA-mediated postconditioning in H9c2 
cells.  Cells were exposed to 6 hours of hypoxia followed by 18 hours of reoxygenation.  For 
the first 45 minutes of reoxygenation the cells were treated with DPCPX (10 µM), paxilline 
(Pax, 1 µM) or iberiotoxin (IbTx, 10 nM) with the addition of CPA (100 nM) for the final 30 
minutes of treatment.    Data expressed as percentage of untreated control (=100%).  Each 
bar represents mean ± S.E.M. of 5 separate experiments, for each experiment the mean was 
taken from 6 replicates.  *** p<0.001 vs. control; ## p<0.01 vs. NS1619; # p<0.05 vs. 
NS1619. 
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6.2.  A model for hypoxia-reoxygenation in rat ventricle strips 
The previous experiments assessed the cytoprotective effects of activation of the 
adenosine A1 receptor and the BKCa channel in H9c2 cells.  To test the hypothesis 
that the BKCa channel is involved in A1 receptor-mediated signal transduction in a 
more physiologically relevant model the contractile function of rat ventricle strips 
following hypoxia with/without pharmacological preconditioning was assessed. One 
strip per heart was taken from the right ventricle wall and set up in an organ bath.  
Control strips were exposed to 40 minutes of oxygenation to allow for equilibration, 
a further 30 minutes oxygenation, 30 minutes hypoxia and then 30 minutes 
reoxygenation – this lead to a 5 ± 2% recovery of function during reoxygenation, 
compared to the loss of function during hypoxia.  The loss of contractile function 
during hypoxia and reoxygenation was measured, and the recovery of function 
during reoxygenation expressed as a percentage of original function compared to the 
loss observed during hypoxia.  For pharmacological preconditioning the agents were 
added for the final 2 minutes of oxygenation then washed out before the onset of 
hypoxia.  Where appropriate, blockers were added for the whole 30 minutes of 
oxygenation.  For hypoxic preconditioning strips were exposed to 40 minutes of 
oxygenation to allow for equilibration, 10 minutes preconditioning hypoxia, 20 
minutes oxygenation, 30 minutes hypoxia and then 30 minutes reoxygenation.  When 
appropriate, strips were exposed to iberiotoxin for 30 minutes prior to the 
preconditioning period of hypoxia. 
Firstly, it was verified that activation of the BKCa channel has a beneficial effect in 
this model.  Preconditioning with NS1619 significantly increased the return of 
contractile function of the ventricle strips during the reperfusion stage (10 µM, 36 ± 
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4% contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.01 
vs. control, see fig.6.7).  To ensure that the response observed was due to the BKCa 
channel ventricle strips were then co-treated with NS1619 and the channel blockers 
paxilline and iberiotoxin.  Preliminary data with 1 µM paxilline did not reveal any 
effect upon the NS1619-mediated return of contractile function (38 ± 4% contractile 
recovery compared to 5 ± 2% observed in control strips, n=4, p<0.001 vs. control, 
see fig.6.7),  10 µM paxilline slightly attenuated the return of response (29 ± 6% 
contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.01 vs. 
control, see fig.6.7); it is possible that the concentrations of paxilline tested were 
insufficient in this model, however, to reduce the number of animals used it was 
decided to continue using solely iberiotoxin to block the BKCa channel.  Iberiotoxin 
considerably decreased the NS1619-mediated effect (50 nM, 14 ± 6% contractile 
recovery compared to 5 ± 2% observed in control strips, n=4, p<0.05 vs. NS1619, 
see fig.6.7), confirming that it was due to activation of the BKCa channel.   
A brief period of hypoxia has been shown to be beneficial against a subsequent, 
prolonged period of hypoxia (hypoxia preconditioning) in many clinical setting and 
models – including the rat ventricle strip (Button et al, 2005).  This study also 
observed a large return of contractile function when strips were preconditioned in 
this manner (35 ± 4% contractile recovery compared to 5 ± 2% observed in control 
strips, n=4, p<0.001 vs. control, see fig.6.8), and found that this could be 
significantly attenuated by treatment with iberiotoxin (50 nM, 18 ± 6% contractile 
recovery compared to 5 ± 2% observed in control strips, n=4, p<0.05 vs. hypoxic 
preconditioning, see fig.6.8).  These data indicate that hypoxic preconditioning in rat 
ventricle strips involves activation of the BKCa channel. 
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Using specific agonists for the adenosine A1, A2A and A3 receptors (CPA, CGS  
21680 and 2-CI-IB-MECA respectively) it was found that activation of the A1 and 
A2A receptors lead to significant return of contractile function (see next paragraphs 
for details), however, a large response with activation of the A3 receptor was not 
observed (1 µM, 13 ± 4% contractile recovery compared to 5 ± 2% observed in 
control strips, n=4, p>0.05 vs. control, data not shown).   
Activation of the A1 receptor with CPA lead to a robust return of function (1 µM, 39 
± 6% contractile recovery compared to 5 ± 2% observed in control strips, n=4, 
p<0.001 vs. control, see fig.6.9) and this was considerably decreased by co-treatment 
with DPCPX (10 µM, 14 ± 5% contractile recovery compared to 5 ± 2% observed in 
control strips, n=4, p<0.01 vs. CPA alone, see fig.6.9) – confirming involvement of 
the A1 receptor.   
Activation of the A2A receptor with CGS 21680 also increased return of function (1 
µM, 32 ± 3% contractile recovery compared to 5 ± 2% observed in control strips, 
n=4, p<0.001 vs. control, see fig.6.10) which was attenuated by co-treatment with the 
A2A antagonist ZM 241385 (12 ± 3% contractile recovery compared to 5 ± 2% 
observed in control strips, n=4, p<0.01 vs. CGS 21680 alone, see fig.6.10).  
Furthermore, return of function mediated by both CPA and CGS 21680 was 
significantly inhibited by co-treatment with 50 nM iberiotoxin (CPA: 14 ± 2% 
contractile recovery compared to 5 ± 2% observed in control strips, n=4, p<0.01 vs. 
CPA alone, see fig.6.9; CGS 21680: 15 ± 3% contractile recovery compared to 5 ± 
2% observed in control strips, n=4, p<0.01 vs. CGS 21680 alone, see fig.6.10).   
These data, for the first time, demonstrate a role for the BKCa channel in adenosine 
A1 and A2A receptor-mediated preconditioning – with evidence regarding the A1 
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receptor collected from both in vitro cell viability work and experiments using an ex-
vivo model measuring mechanical function. 
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Figure 6.7: The role of the BKCa channel in NS1619-mediated pharmacological 
preconditioning in rat ventricle strips.  Rat ventricle strips were pretreated with paxiline 
(Pax; 10 µM) or iberiotoxin (IbTx, 50 nM) for 30 minutes prior to cardioprotection induced 
by 10 µM NS1619.  Data expressed as a percentage of contractile recovery compared to the 
level of recovery observed in control strips exposed to 30 minutes hypoxia alone.  Each bar 
represents mean ± S.E.M. of 4 experiments. *** p<0.001 vs. hypoxia control; ** p<0.01 vs. 
hypoxia control; # p<0.05 vs. NS1619 alone. 
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Figure 6.8: The role of the BKCa channel in hypoxic preconditioning in rat ventricle 
strips.  Rat ventricle strips were pretreated with iberiotoxin (IbTx, 50 nM) for 30 minutes 
prior to cardioprotection induced by hypoxic preconditioning (HPC).  Data expressed as a 
percentage of contractile recovery compared to the level of recovery observed in control 
strips exposed to 30 minutes hypoxia alone.  Each bar represents mean ± S.E.M. of 4 
experiments. *** p<0.001 vs. hypoxia control; # p<0.05 vs. HPC alone. 
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Figure 6.9: The role of the BKCa channel in pharmacological preconditioning mediated 
by the adenosine A1 receptor in rat ventricle strips. Rat ventricle strips were pretreated 
with iberiotoxin (IbTx; 50 nM) or DPCPX (A1 antagonist, 10 µM) for 30 minutes prior to 
cardioprotection induced by 1 µM CPA.  Data expressed as a percentage of contractile 
recovery compared to the level of recovery observed in control strips exposed to 30 minutes 
hypoxia alone.  Each bar represents mean ± S.E.M. of 4 experiments.  *** p<0.001 vs. 
hypoxia control; ## p<0.01 vs. CPA alone. 
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Figure 6.10: The role of the BKCa channel in pharmacological preconditioning 
mediated by the adenosine A2A receptor in rat ventricle strips. Rat ventricle strips were 
pretreated with iberiotoxin (IbTx; 50 nM) or ZM 241385 (A2A antagonist, 1 µM) for 30 
minutes prior to cardioprotection induced by 1 µM CGS 21680.  Data expressed as a 
percentage of contractile recovery compared to the level of recovery observed in control 
strips exposed to 30 minutes hypoxia alone.  Each bar represents mean ± S.E.M. of 4 
experiments.  *** p<0.001 vs. hypoxia control; ## p<0.01 vs. CGS 21680 alone. 
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7. Discussion 
7.1. Summary of main findings 
i)  H9c2 myocardial cell model 
Cytoprotection
A1 Receptor
BKCa channel
ERK1/2
?
 
Figure 7.1.i) Cytoprotective signal transduction in H9c2 cells.  Activation of the 
adenosine A1 receptor leads to protection against hypoxia and hypoxia-reoxygenation-
induced cell death, and this involves activation of the BKCa channel and possibly ERK1/2.  
Black arrow = well documented event; red arrow = possible link; blue arrow = novel 
pathway. 
 
ii)  Rat ventricle strip model 
HPC A1 receptor A2A receptor
BKCa channel
Enhanced recovery of function
 
Figure 7.1.ii) The BKCa channel in cardioprotection of rat ventricle strips.  For the first 
time it has been shown that the BKCa channel mediates cardioprotection triggered by hypoxic 
preconditioning (HPC) and activation of adenosine A1 and A2A receptors in rat ventricle 
strips.     
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Figure 7.1.i) summarizes the main findings from this current project using H9c2 
cells.  It was shown that pharmacological activation of the adenosine A1 receptor and 
the BKCa channel both lead to protection against hypoxia and hypoxia-
reoxygenation-induced cell death.  Regarding hypoxia-reoxygenation-induced 
damage, the A1 receptor agonist CPA was most beneficial as a preconditioning agent, 
whereas the BKCa channel activator NS1619 was most beneficial as a 
postconditioning agent.  Interestingly, the protection afforded by A1 receptor 
activation was abolished by blockade of the BKCa channel – implying that the 
cytoprotective signal transduction pathway triggered by this receptor involves 
activation of the BKCa channel.  However, the role of ERK1/2 in this pathway 
remains controversial; more work is required to elucidate whether ERK1/2 activation 
occurs upstream of BKCa channel activation, or not at all. 
Figure 7.1.ii) summarizes the findings from the work with the rat ventricle strip 
model.  Hypoxic preconditioning and pharmacological preconditioning with agonists 
at the adenosine A1 receptor (CPA) and the A2A receptor (CGS 21680) all led to 
significantly enhanced contractile recovery following a hypoxic insult.  Blockade of 
the BKCa channel prevented such preconditioning, showing that the this channel has 
an important role in preconditioning of rat ventricle strips mediated by hypoxia, 
activation of the adenosine A1 receptor and activation of the adenosine A2A receptor. 
For the first time, and in two different models, a role for the BKCa channel in 
adenosine receptor-mediated cytoprotective signal transduction has been 
demonstrated. 
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7.2.  Characterisation of GPCRs functionally expressed on H9c2 cells 
i)   Adenosine receptors 
This report provides evidence for the functional expression of Gi-coupled adenosine 
A1 receptors on myocardial H9c2 cells.  The specific A1 receptor agonist CPA 
provided a robust inhibition of forskolin-stimulated [
3
H]-cAMP accumulation, which 
was reversed by the Gi-protein blocker pertussis toxin (PTX) and the specific 
adenosine A1 receptor antagonist DPCPX.  The adenosine A3 receptor agonist CI-IB-
MECA did not inhibit cAMP accumulation, but at a high concentration actually 
amplified the forskolin response; interestingly, this was blocked by DPCPX but not 
the A3 receptor antagonist MRS 1220.  This observation is suggestive of a non-
specific action of CI-IB-MECA resulting in A1 activation, indeed this was reported 
by Kilpatrick et al (2001) who showed that CI-IB-MECA-induced cardioprotection 
was blocked by DPCPX.   
The adenosine A1 receptor usually couples to Gi protein, producing an inhibitory 
effect on adenylyl cyclase, but it has been shown that high agonist concentrations can 
lead an increase in cAMP production (Cordeaux et al, 2004).  This biphasic adenylyl 
cyclase response following A1 receptor activation is due to direct coupling of the A1 
receptor with both Gi and Gs protein; and agonist potency at the Gs-coupled A1 
receptor was in the micromolar range, compared to nanomolar responses at the Gi-
coupled receptor (Cordeaux et al, 2004; Baker & Hill, 2007).  This finding is in 
keeping with the biphasic cAMP response to CPA observed in this current report, 
and could explain the increase in cAMP measured following treatment with 10 µM 
CI-IB-MECA.   
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A previous report showed that stimulation of the A1 receptor transiently activates 
ERK1/2 in cardiomyocytes (Germack & Dickenson, 2004).  In this current report a 
robust CPA-induced ERK1/2 phosphorylation was also observed in the H9c2 cell 
line, further validating a functional role for the A1 receptor in these cells. 
The data presented in this report indicate that adenosine A2A receptors are not 
functionally expressed on H9c2 cells.  This is in contrast to a recent study by 
Urmaliya et al (2009), which described cooperation between adenosine A1 and A2A 
receptors in cardioprotection in H9c2 cells.  The latter study exposed H9c2 cells to 
hypoxia (100% N2) for 12 hours, and noticed that protection against necrosis 
mediated by a selective A1 receptor agonist could be attenuated with a selective A2A 
receptor antagonist.  It was also noticed that co-treatment with the A1 and A2A 
agonists potentiated the effect of the A1 agonist alone, but treatment with only the 
A2A agonist had no effect – suggesting that the receptors are working together during 
hypoxia.  The presence of the A2A receptor in this H9c2 cell model, but not in the 
functional study in this current report, could be explained by the experimental 
conditions.  It has been demonstrated that adenosine A2A receptor mRNA and protein 
levels are increased during hypoxia in PC12 cells (Kobayashi & Millhorn, 1999), 
with a maximum of ~250% increase in mRNA and ~400% increase in protein 
occurring at 12 hours of hypoxia.  It is therefore likely that the expression of A2A 
receptors on H9c2 cells is low during normal conditions (and so not detectable by 
functional assay), but 12 hours of hypoxic incubation stimulates a substantial 
increase in receptor expression so the effects of A2A receptor signalling reach a 
detectable level.     
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ii) Opioid receptors 
κ-opioid receptors are the predominant subtype of opioid receptor in the heart; and 
results suggest that these Gi-coupled receptors are also expressed on H9c2 cells.  
However, no evidence was uncovered for functional expression of δ-opioid 
receptors.  Research suggests that κ-opioid receptors account for 80% of opioid 
receptors expressed in immature rat hearts (Zimlichman et al, 1996), and expression 
of δ-opioid receptors increases with postnatal development.  As H9c2 cells are 
derived from embryonic rat heart (Kimes & Brandt, 1976) this could explain the lack 
of functional δ-opioid receptors. 
During these experiments it was found that treatment with pertussis toxin (PTX) 
actually decreased forskolin-induced cAMP accumulation.  This was also observed 
by Robinson & Caron (1997), who noticed that this effect only occurred with 
HEK293 cells expressing adenylyl cyclase type V.  It is thought that PTX may 
increase intracellular Ca
2+
, which would inhibit the calcium-sensitive adenylyl 
cyclase type V – which is the predominant isoform of adenylyl cyclase expressed in 
the heart, possibly explaining the observed effect in the heart-derived H9c2 cells 
(Ebina et al, 1997). 
iii) β-adrenergic receptors 
The data in this report regarding β2-adrenergic receptor expression implies that these 
receptors are expressed on H9c2 cells, but the data regarding β1 receptor expression 
is less convincing.  A study using receptor mRNA levels and radioligand binding 
assays to investigate β-adrenergic receptor expression on H9c2 cells reported a 
29%:71% ratio in favour of the β2 receptor (Dangel et al, 1996), but another study 
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using antibody imaging reported modest expression of both subtypes (Ianoul et al, 
2005); it is possible that discrepancies regarding expression of the receptor subtypes 
on H9c2 cells arise from the different methods utilised.  Taking all of these data into 
account, it can be inferred that β2-adrenergic receptors are expressed on H9c2 cells. 
Evidence has also been presented supporting the functional expression of a UTP-
sensitive Gq-coupled P2Y receptor on H9c2 cells.  To date, this is the first study 
looking into the functional expression of GPCRs on H9c2 cells; if time permitted it 
would be interesting to expand on this body of information by confirming the results 
using other techniques (e.g. Ca
2+
 mobilization for Gq-coupled receptors) and 
increasing the selection of receptors tested. 
 
7.2. The cardioprotective potential of functionally expressed receptors and K+ 
channels on H9c2 cells 
 
i) Adenosine A1 receptor 
H9c2 cells are commonly used for studies into cardioprotection, as they display 
similar biochemical and electrophysiological properties to cardiac tissue (Hescheler 
et al, 1991) but are less demanding to culture (Zordoky & El-Kadi, 2007).  
Activation of the Gi-coupled adenosine A1 receptor has a well-documented role in 
cardioprotection in many models, including primary rat cardiomyocytes (Safran et al, 
2001; Fei et al, 2009), so it was proposed that this would also be the case in H9c2 
cells.  Stimulation of the adenosine A1 receptor with the selective agonist CPA, prior 
to 6 hours hypoxic incubation, significantly increased mitochondrial reduction of 
MTT, and decreased LDH release and caspase-3 activity.  Loss of mitochondrial 
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function or cell membrane integrity (as measured by MTT metabolism and LDH 
leakage, respectively) signifies irreversible cell death (i.e. necrosis), but can also 
occur at the late stages of apoptosis, so caspase-3 activity (which is specific to 
apoptosis) was also measured to fully distinguish between necrosis and apoptosis.  
These findings (that CPA increased mitochondrial reduction of MTT, and decreased 
LDH release and caspase-3 activity) point to a role for the A1 receptor in regulation 
of apoptosis and necrosis during hypoxia - confirming the receptors part in 
cardioprotection.  This role for the A1 receptor in both apoptosis and necrosis has 
also been documented in murine hearts; in isolated hearts from transgenic mice over-
expressing the cardiac A1 receptor it was reported that, following 
ischaemia/reperfusion, less apoptosis and less necrosis occurred compared to wild-
type controls (Regan et al, 2003). 
ii) κ-opioid receptor 
Activation of the Gi-coupled κ-opioid receptor with (-)-U-50488 conferred a different 
pattern of protection to the adenosine A1 receptor.  Hypoxia-induced LDH release 
was attenuated, but neither MTT metabolism or caspase-3 activity were affected.  
This suggests that activation of the κ-opioid receptor provides some protection 
against necrotic cell death in H9c2 cells, but does not modulate apoptosis or 
mitochondrial function.  There is great variability regarding the anti-apoptotic nature 
of the κ-opioid receptor when using different experimental models; one study stated 
that activation of κ-opioid receptors in a human epithelial tumour cell line increased 
apoptosis (Diao et al, 2000), but more recently activation of this receptor has been 
reported to attenuate myocardial apoptosis following ischaemia/reperfusion (Rong et 
al, 2009).  When measuring different parameters, even the beneficial role of cardiac 
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κ-opioid receptor activation can be questioned, as activation of such receptors can be 
arrhythmogenic during ischaemia/reperfusion (Wong et al, 1990).  The role of the κ-
opioid receptor may be well documented in cardioprotection, but it is important to 
note that inconsistencies do arise between different in vitro and in vivo models. 
iii) β-adrenergic receptors  
As mentioned previously, the role of β-adrenergic receptor activation in 
cardioprotection is unclear and appears to differ between various models and 
experimental procedures.  In this current study it was found that the non-selective β-
adrenergic receptor agonist isoprenaline significantly attenuated hypoxia-induced 
caspase-3 activity in H9c2 cells.  The functional receptor assays implied that the β2 
but not β1 adrenergic receptor was present on these cells; the β2 receptor has a well 
documented role in cardioprotection (Tong et al, 2005), and the β1 receptor 
reportedly has a role in cardioprotection and ischaemia-reperfusion injury (Spear et 
al, 2007).  It is thought that the cardioprotective properties of β-adrenergic receptor 
activation arise from coupling of β2 receptors with Gi protein, which is dependent on 
PKA activity (Tong et al, 2005) - PKA phosphorylates the receptor, creating a higher 
affinity for Gi protein over Gs protein, and inhibition of PKA has been shown to 
block isoprenaline-mediated cardioprotection in mouse hearts (Tong et al, 2005).  
Taking this into account, it could be presumed that the effect observed from 
isoprenaline is mediated by the β2 receptor.  However, in this case it is interesting to 
note that the selective β2 agonist procaterol did not provide any significant protection 
against hypoxia-induced cell death (as measured my MTT reduction, LDH release 
and caspase-3 activity) in H9c2 cells, but did increase MTT reduction in control cells 
exposed to 6 hours normoxia in glucose and serum-free DMEM.  It is possible that 
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this is mediated by a non-β2 adrenergic receptor effect, otherwise it would be 
expected that isoprenaline would also induce an increase in MTT reduction.           
Overall, from the agonists used in this study it can be concluded that stimulation of 
the adenosine A1 receptor provided the greatest cardioprotective effect in H9c2 cells. 
iv)  KATP and BKCa channels 
Activation of mitochondrial KATP and BKCa channels are reported to protect against 
ischemic injury (Ardehali, 2005), and this also appears to be the case when H9c2 
cells are exposed to a 6 hour hypoxic insult.  Both diazoxide (KATP activator) and 
NS1619 (BKCa activator) significantly reduced LDH release, which was blocked by 
specific channel inhibitors (5-HD, KATP inhibitor; paxilline and iberiotoxin, BKCa 
inhibitors).  NS1619 also significantly inhibited hypoxia-induced caspase-3 activity, 
suggesting an anti-apoptotic role for the BKCa channel in H9c2 cells.   
It has been reported that NS1619-induced delayed neuronal preconditioning occurs 
independently of the BKCa channel, and is instead mediated by activation of the 
PI3K/PKB pathway, generation of reactive oxygen species and inhibition of caspases 
(Gáspár et al, 2008).  Taking this into account two specific BKCa channel inhibitors 
(paxilline and iberiotoxin) were used in this present study to confirm the presence of 
a BKCa channel in H9c2 cells via NS1619-mediated cytoprotection, however, there is 
doubt surrounding the specificity of diazoxide for KATP channels.  Kim et al (2006) 
suggest that activation of KATP channels by diazoxide is indirect, with diazoxide 
inducing translocation of PKC which then leads to opening of KATP channels.  
Alternatively, Dröse et al (2006) found that diazoxide induced oxidation of a reactive 
oxygen species indicator in the absence of potassium or ATP, so questioning the 
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involvement of KATP channels.  This article also postulated that 5-HD acts as a 
metabolic substrate rather than an inhibitor of KATP channels.  Despite these 
reservations regarding the specific actions of diazoxide, it is still widely accepted that 
it has a role in cardioprotection. 
Due to the large body of work and knowledge regarding mitoKATP channels, it was 
decided to concentrate on BKCa channels for the remainder of the project.  However, 
by finding evidence for functional expression of KATP channels the expression profile 
of receptors and channels on H9c2 cells has been expanded.   
Although mitochondrial, not sarcolemmal, BKCa channels are reported to be 
expressed in myocardial cells, the BKCa channel opener NS1619 does not 
discriminate between channels expressed at the two locations so further investigation 
was required to uncover the location of BKCa channels in H9c2 cells.  By probing the 
mitochondrial and cytoplasmic fractions of these cells with antibodies specific to the 
α and β4 subunits of the BKCa channel it was shown that myocardial H9c2 cells 
express a BKCa channel in the mitochondria, but not cytoplasm (therefore, not in the 
sarcolemmal membrane).  As mentioned previously, mitochondrial BKCa channels 
are reported to be expressed in cardiomyocytes but the presence of a plasma 
membrane channel is less definite (Ko et al, 2009), so this finding is as expected.  
Interestingly, the BKCa channel β4 subunit is believed to be the predominant subunit 
in the brain, with β1 mainly expressed in the heart (Piwonska et al, 2008; Jiang et al, 
1999) – but the use of a β1-specific antibody did not provide evidence for protein 
expression of this subtype in H9c2 cells (data not shown).  However, a study using 
RT-PCR has identified both the β1 and β4 subunits in rat cardiac tissue (Poulsen et 
al, 2009), demonstrating that the β4 subunit is not purely localised to neural tissue.  
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BKCa channels with associated β4 subunits are less sensitive to the channel blockers 
charybdotoxin and iberiotoxin (Meera et al, 2000), so the presence of the β4 subunit 
in H9c2 cells could explain why iberiotoxin did not block NS1619-mediated 
cytoprotection as fully as paxilline in this report.     
In conclusion, BKCa channels display cytoprotective properties in H9c2 cells, and the 
channels in question are located to the mitochondria.  These mitochondrial BKCa 
channels have been linked with signalling pathways mediated by GPCR agonists 
such as (-)-U-50488 (Cao et al, 2005) and adrenomedullin (Nishida et al, 2008), but 
for the first time this present study discovered a link between mitochondrial BKCa 
channels and adenosine A1 receptor-mediated signal transduction.  It was revealed 
that hypoxia-induced LDH release and caspase-3 activity were attenuated by pre-
treatment with CPA, the selective adenosine A1 receptor agonist, and this effect 
could be reversed by blockade of the BKCa channel with paxilline and iberiotoxin.  
This finding demonstrates that BKCa channels (presumably mitochondrial BKCa 
channels) mediate the cytoprotective and anti-apoptotic effects of the adenosine A1 
receptor against hypoxia-induced cell death in H9c2 cells. 
 
7.3. The role of protein kinases ERK1/2 and PKB in adenosine A1 
receptor and BKCa channel-mediated cytoprotection 
 
Having shown that stimulation of the adenosine A1 receptor can lead to activation of 
the BKCa channel it was then postulated that cellular protein kinases mediate some of 
the intermediate signal transduction pathways.  Extracellular signal-regulated kinase 
1/2 (ERK1/2) and protein kinase B (PKB) have well documented roles in the 
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Reperfusion Injury Salvage Kinase (RISK) pathway (Hausenley et al, 2007), and 
have both been implicated in cardioprotection mediated by adenosine receptors 
(Germack & Dickenson, 2005; Germack et al, 2004) and mitochondrial KATP 
channels (de Toit et al, 2008; Grossini et al, 2009), so it was postulated that they may 
be involved in A1 receptor/BKCa channel signalling in H9c2 cells.  Initially, cells 
were treated with 10 µM NS1619 for varying amounts of time, but at no point was an 
increase in ERK1/2 or PKB phosphorylation observed.  It was then decided to use 
100 µM NS1619, as one study reported that this activates PKB in neurones (although 
by a BKCa channel-independent mechanism; Gáspár et al, 2008).  However, this 
finding was not replicated in H9c2 cells – in fact 100 µM NS1619 significantly 
inhibited phosphorylation of PKB, and ERK1/2.  It is likely that due to the high 
concentration used, the observed effects of NS1619 on dephosphorylation of ERK1/2 
and PKB are independent of the BKCa channel – possibly occurring via activation of 
a phosphatase.  It is interesting to note that Quercetin, a flavonoid which is reported 
to activate BKCa channels in coronary arteries (Cogolludo et al, 2007), also 
dephosphorylates ERK1/2 and PKB when used at a high concentration (Spencer et 
al, 2003).    
As PKB and ERK1/2 are both cell survival kinases activated during periods of stress, 
and activation of the BKCa channel has an anti-apoptotic effect in H9c2 cells, it was 
proposed that increased phosphorylation of these kinases may be observed during 
hypoxia following pre-treatment with NS1619 (10 µM); however this was not 
observed – suggesting that the anti-apoptotic effect of BKCa channel-mediated 
signalling occurs independently of ERK1/2 and PKB, or that BKCa channel activation 
occurs downstream of ERK1/2 or PKB phosphorylation.  It is interesting to note that 
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activation of both of these protein kinases has been reported following 
pharmacological activation of the mitochondrial KATP channel, implying that the 
anti-apoptotic effects of the mitochondrial KATP channel and the BKCa channel are 
differentially mediated (Ahmad et al, 2006; Naitohel et al, 2006).     
An alternative explanation is that compartmentalisation of ERK1/2 and PKB occurs 
upon activation.  During the resting state of a cell ERK1/2 and PKB are distributed 
throughout the cytoplasm, but both have been reported to localise elsewhere when 
activated.  Despite the lack of a nuclear localisation signal ERK1/2 has been found to 
accumulate in the nucleus upon activation (Chuderland et al, 2008), where is then 
able to generate signal responses most effectively.  Translocation of PKB to the 
mitochondria upon activation is reported in rat cardiomyocytes, where it then exerts 
an anti-apoptotic effect by phosphorylating hexokinase-II which prevents opening of 
the mPTP (Miyamoto et al, 2008).  If this was the case, phosphorylation of ERK1/2 
or PKB at specific subcellular localities may not be apparent when using whole cell 
lysates. 
Activation of the adenosine A1 receptor with CPA has been reported to produce an 
increase in activity of ERK1/2 and PKB in rat cardiomyocytes (Gemack & 
Dickenson, 2004; Germack et al, 2004).  In H9c2 cells CPA produced a significant, 
transient increase in ERK1/2 phosphorylation, but had no effect on PKB – suggesting 
that in these cells adenosine A1 receptor signalling is mediated by ERK1/2 but not 
PKB.   
Using the knowledge that adenosine A1 receptor stimulation leads to activation of 
ERK1/2 and the BKCa channel, it was hypothesised that ERK1/2 forms part of the A1 
receptor/BKCa channel signal transduction pathway.  However, in H9c2 cells 
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blockade of the BKCa channel did not affect CPA-mediated ERK1/2 activation – 
suggesting that these kinases are not phosphorylated downstream of the BKCa 
channel.   
Overall, these data suggest that activation of the BKCa channel, and the signalling 
pathway between adenosine A1 receptors and the BKCa channel, are likely to occur 
independently of ERK1/2 and PKB activation in H9c2 cells.     
 
7.4. The role of the BKCa channel in adenosine receptor-mediated 
protection against hypoxia-reoxygenation 
 
i) A model for hypoxia-reoxygenation in H9c2 cells 
Studies into protection against hypoxia-induced cell death are important to help 
elucidate the mechanisms involved in such phenomena, but models using hypoxia-
reoxygenation can provide more clinically relevant data, especially when relating to 
myocardial infarction.  By creating a model for hypoxia-reoxygenation in H9c2 cells 
it was possible to then test the pre- and postconditioning potential of 
pharmacological activation the adenosine A1 receptor and the BKCa channel.  It was 
observed that a protocol of 6 hours hypoxia (0.5% O2 with glucose/serum-free 
DMEM to mimic ischaemia) followed by 18 hours reoxygenation (DMEM 
containing glucose and 1% serum) was sufficient to induce necrotic cell death, as 
measured by LDH release.  No caspase-3 activity was observed though, indicating 
that apoptosis had not occurred.  Nevertheless, it is possible that during the 24 hour 
long protocol of hypoxia and reoxygenation, any cell death initiated by hypoxia 
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could have progressed beyond the apoptotic stage – consequentially caspase-3 would 
not be detected but LDH would be released from the damaged and dying cells. 
ii) Pre- and postconditioning in H9c2 cells 
Pre-treating H9c2 cells with CPA prior to the period of hypoxia did not have any 
effect on LDH release, implying that adenosine A1 receptor-mediated 
pharmacological preconditioning is not protective in H9c2 cells.  Interestingly, 
preconditioning with NS1619 augmented LDH release, and this was reversed with 
paxilline and iberiotoxin – indicating that pharmacological preconditioning via 
activation of the BKCa channel amplifies cell death in this model.  This finding 
contrasts with the majority of reports regarding BKCa channels in preconditioning, so 
more work would be required to uncover the mechanisms involved.  It is possible 
that the observed increase in LDH release could be a cell specific effect, or due to the 
experimental protocol used.  It has been shown that the time of agonist/antagonist 
treatment can greatly affect the experimental outcome.  For example, Schröter et al 
(2005) found that excitotoxic NMDA receptor-evoked rises in neuronal intracellular 
calcium could be attenuated by pre-treatment with nitric oxide,  but nitric oxide 
treatment at the time of NMDA receptor stimulation actually potentiated the toxicity.  
Therefore it can be expected that the treatment protocol used would affect the end 
result.  
Conversely, activation of the BKCa channel during the first few minutes of 
reoxygenation (i.e. postconditioning) significantly reduced hypoxia-reoxygenation-
induced LDH release.  This was also attenuated by co-treatment with paxilline and 
iberiotoxin, suggesting that the effect was mediated by the BKCa channel.  Currently, 
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this is the first report of postconditioning triggered by direct activation of the BKCa 
channel. 
Despite the lack of efficacy of CPA as a preconditioning agent, activation of the 
adenosine A1 receptor created a postconditioning effect in H9c2 cells as LDH release 
was significantly reduced.  Not only was this reversed by antagonism of the A1 
receptor, but also by blockade of the BKCa channel – providing the first evidence of a 
role for the BKCa channel in adenosine A1 receptor-mediated postconditioning. 
iii) Preconditioning in rat ventricle strips 
To validate the use of H9c2 cells as a model for investigating adenosine A1 receptor 
and BKCa channel mediated signalling, it was decided to verify the observed results 
in a more physiologically relevant model.  Strips of rat ventricle are often used as a 
method for measuring mechanical contractile function of the tissue following various 
treatment protocols (for examples see: Button et al, 2005; Bravo et al, 2007; Vassallo 
et al, 2008; ).  In this case, strips from the right ventricle were used as the right 
ventricle wall is thinner than the left, allowing for greater penetration of drugs.  
Following a period of hypoxia (glucose/oxygen-free KREBS solution to mimic 
ischaemia) contractile function of the ventricle strips returned to approximately 5% 
of that observed prior to hypoxia, i.e. the control phase.  This was important as it 
conveyed that the tissue was still viable – if there had been no return of function it 
would be possible that the tissue had died, therefore the beneficial effects of 
preconditioning would be masked.   
Preconditioning with NS1619 significantly enhanced the return of contractile 
function following hypoxia, and this was blocked by iberiotoxin.  This is the first 
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time that activation of the BKCa channel has been investigated, and indeed shown to 
be beneficial, in this model.  Hypoxic preconditioning has been well documented in 
many different models, including rat ventricle strips (Button et al, 2005).  However, 
in this model the role of the BKCa channel had not been examined.  This present 
study demonstrates that blockade of the BKCa channel is sufficient to significantly 
inhibit the effect of hypoxic preconditioning in rat ventricle strips.   
Preconditioning with selective agonists of adenosine A1, A2A and A3 receptors has 
previously been reported to increase the return of contractile function in this rat 
ventricle strip model (Button et al, 2005).  However, in this current study it was 
observed that the A1 and A2A receptors were capable of inducing preconditioning, but 
not the A3 receptor.  There is no obvious explanation for this discrepancy, as the 
same drug was used at the same concentration in both studies (2-CI-IB-MECA, 1 
µM) – more work would need to be done to clarify the effects of adenosine A3 
receptor activation.      
The roles of the A1 and A2A receptors in preconditioning of rat ventricle strips were 
confirmed with the observation that the beneficial effect of pre-treating with an 
agonist at either receptor was blocked by co-treatment with a receptor-appropriate 
antagonist.  Following on from earlier work with H9c2 cells, it was postulated that 
the BKCa channel – direct stimulation of which has been proven to be beneficial in 
both the H9c2 cell viability model and the ventricle tissue mechanical function 
model -  was also involved in A1 receptor-mediated preconditioning in rat ventricle 
strips.  Indeed this was the case, as co-treatment with the A1 receptor agonist CPA 
and the BKCa channel blocker iberiotoxin significantly attenuated the protective 
effect afforded by treatment with CPA alone.   
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This study also revealed that blockade of the BKCa channel could inhibit 
preconditioning mediated by the Gs-coupled adenosine A2A receptor in rat ventricle 
strips.  Although the adenosine A1 and A2A receptors couple to different G proteins, 
they are both reported to activate ERK1/2 (Germack & Dickenson, 2004).  It is 
possible, therefore, that in rat ventricle strips this common ground of ERK1/2 
activation provides an intermediate step between adenosine receptor stimulation and 
BKCa channel activation, or is a consequence of BKCa channel signalling.  It would 
be interesting to further research the signal transduction pathways involving 
adenosine receptors and the BKCa channel, as this current report demonstrates a 
beneficial effect of such pathway activation in two separate models. 
 
7.5. Conclusions and further work 
i) General conclusions 
Overall, this body of work has provided novel data supporting a role for the BKCa 
channel in adenosine A1 receptor-mediated protection against hypoxia and hypoxia-
reoxygenation-induced cell death in a H9c2 myocardial cell model.  This data was 
then validated using a model utilising isolated rat ventricle strips, and it was 
discovered that in this more physiologically relevant model the BKCa channel has a 
pivotal role in hypoxic preconditioning and in pharmacological preconditioning 
mediated by the adenosine A1 and adenosine A2A receptors. 
ii) Further work 
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If this body of work were to be extended, it would be important to elucidate the 
signal transduction pathway that occurs between the adenosine A1 and A2A receptors 
and the BKCa channel.  Regarding the H9c2 cell model, by using subcellular 
fractionation it would be possible to probe distinct localities of the cells for protein 
kinase activity.  The possible role of ERK1/2 and PKB could then be uncovered, and 
PKA, PKC and PKG would also make good targets for future work as they have all 
been linked with adenosine A1 receptor-mediated signalling and/or BKCa channel-
mediated signalling.  Inhibitors of PKA, PKC and PKG are also commercially 
available, therefore increasing the scope for examining the signalling pathways and 
determining the triggers, modulators and effectors. 
Although there is not a commercially available direct inhibitor of ERK1/2, inhibitors 
of MEK1/2 are available (e.g. PD 98059) and are often used to study ERK1/2-
mediated responses.  The role of ERK1/2 as an upstream second messenger in 
adenosine A1 receptor-mediated signalling is confirmed, but it is not known if 
ERK1/2 is part of the BKCa channel signalling pathway.  By preventing ERK1/2 
activity via inhibition of MEK1/2 it would be possible to elucidate whether ERK1/2 
phosphorylation occurs upstream of the BKCa channel, as if this was the case 
inhibition of ERK1/2 would prevent NS1619-mediated protection.  
Due to the anti-apoptotic nature of adenosine A1 receptors and BKCa channel 
activation, it is likely that the signal pathway between these two proteins focuses on 
the mitochondria.  Activation of the mitochondrial BKCa channel has been reported 
to reduce Ca
2+
 overload (Kang et al, 2007), which would create an environment 
favouring closure of the mPTP – indeed it has already been suggested that the mPTP 
is a downstream modulator of BKCa channel signalling (Cao et al, 2005 & 2005a; 
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Gao et al, 2005), and that adenosine A1 receptor activation leads to inhibition of 
mPTP (Fei et al, 2009), so it appears quite likely that the anti-apoptotic effects of the 
adenosine A1 receptor/BKCa channel-mediated signal transduction pathway arises 
from inhibition of the mPTP.  As yet though, this has not been looked into. 
Another area of interest would be to determine the BKCa channel subtype/s expressed 
and responsible for A1 receptor/BKCa channel-mediated cardioprotection in the rat 
heart.  Western blotting with antibodies to the specific subtypes would reveal which 
are expressed, and then by using knock-out animals lacking the individual subtypes it 
would be possible to 1) ascertain the general effects of knocking out each BKCa 
channel subunit (e.g. β1 or β4), and 2) establish if cardioprotection triggered by the 
adenosine A1 receptor can still take place.   
A further avenue to explore would be whether the expressions of BKCa channel 
subunits are upregulated following treatment.  It has been shown that the KATP 
channel – which has a well documented role in preconditioning – contains a hypoxia-
inducible Kir6.1 subunit (Melamed-Frank et al, 2001); is this also the case for the 
BKCa channel and if so is this effect modulated by adenosine receptor activation? 
iii) Concluding remarks 
In conclusion, this study has shown that activation of the BKCa channel can provide 
protection against hypoxia and hypoxia-reoxygenation-induced cell death and loss of 
function, and that these effects are mediated by adenosine receptor signalling.  
Alongside the potential cardioprotective properties, opening of the BKCa channel has 
been proposed to be beneficial in ischaemic stroke.  In vivo experiments using the 
BKCa channel opener BMS-204352 have shown very promising data, but clinical 
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trials were disappointing (Jenson, 2002), highlighting the need for more research into 
the mechanisms involved in BKCa channel-mediated signalling.  The data in this 
current report will contribute to the increasing body of knowledge regarding BKCa 
channel-mediated signal transduction, and hopefully lead to further investigation and 
potential drug discovery.     
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